{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:20:40Z","timestamp":1793744440387,"version":"4.6.1"},"reference-count":305,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science and Technology Major Projects of China","award":["2025ZD1801002"],"award-info":[{"award-number":["2025ZD1801002"]}]},{"name":"Interdisciplinary Research Matching Scheme (IRMS) of Hong Kong Baptist University","award":["RC-IRMS\/13-14\/03"],"award-info":[{"award-number":["RC-IRMS\/13-14\/03"]}],"id":[{"id":"https:\/\/ror.org\/0145fw131","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Insulin is an important endocrine peptide hormone with pleiotropic effects on metabolic regulation and cellular growth. Insulin resistance (IR), characterized by insensitivity of metabolic tissues to insulin stimulation, has emerged as a major impediment to overall metabolic health. Triggered by multiple environmental factors and genetic predisposition, IR paves the way for several related diseases, including metabolic associated diseases, cardiovascular diseases and cancer. Of note, the liver plays a central role in whole-body metabolism and is the portal encountering high concentrations of insulin. Excess glucose, lipids and the compensatory hyperinsulinemia resulting from IR may collectively impose a huge burden on the liver, driving the progression of chronic liver diseases and fostering a pro-carcinogenic environment by increasing mutagenic susceptibility and angiogenic dysregulation. Better understanding of this mechanistic link is important to highlight the underestimated role of IR in progressive diseases and may contribute to stratified diagnosis and treatment. This review summarizes the risk factors and molecular mechanisms of IR, with a specific focus on its role in carcinogenesis, taking hepatocellular carcinoma (HCC) as an example. Finally, we discuss the effective lifestyle and pharmacological interventions for IR and emphasize the necessity of incorporating IR management into the prevention, stratified diagnosis and treatment of HCC.<\/jats:p>","DOI":"10.1186\/s43556-026-00408-5","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:03:10Z","timestamp":1770768190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Insulin resistance: mechanisms and therapeutic interventions"],"prefix":"10.1186","volume":"7","author":[{"given":"Liuchunyang","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxiu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3840-5292","authenticated-orcid":false,"given":"Yuanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"408_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4093\/dmj.2021.0280","volume":"46","author":"S-H Lee","year":"2021","unstructured":"Lee S-H, Park S-Y, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J. 2021;46:15\u201337. https:\/\/doi.org\/10.4093\/dmj.2021.0280.","journal-title":"Diabetes Metab J"},{"key":"408_CR2","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41580-021-00390-6","volume":"22","author":"DE James","year":"2021","unstructured":"James DE, St\u00f6ckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol. 2021;22:751\u201371. https:\/\/doi.org\/10.1038\/s41580-021-00390-6.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"408_CR3","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/curroncol31020075","volume":"31","author":"L Szablewski","year":"2024","unstructured":"Szablewski L. Insulin resistance: the increased risk of cancers. Curr Oncol. 2024;31:998\u20131027. https:\/\/doi.org\/10.3390\/curroncol31020075.","journal-title":"Curr Oncol"},{"key":"408_CR4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/biomedicines12071417","volume":"12","author":"S Fazio","year":"2024","unstructured":"Fazio S, Affuso F, Cesaro A, Tibullo L, Fazio V, Calabr\u00f2 P. Insulin resistance\/hyperinsulinemia as an independent risk factor that has been overlooked for too long. Biomedicines. 2024;12:1417. https:\/\/doi.org\/10.3390\/biomedicines12071417.","journal-title":"Biomedicines"},{"key":"408_CR5","doi-asserted-by":"publisher","unstructured":"Saltiel AR. Insulin signaling in health and disease. J Clin Invest. 2021;131. https:\/\/doi.org\/10.1172\/JCI142241.","DOI":"10.1172\/JCI142241"},{"key":"408_CR6","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.gendis.2022.03.016","volume":"10","author":"J Iqbal","year":"2023","unstructured":"Iqbal J, Jiang H-L, Wu H-X, Li L, Zhou Y-H, Hu N, et al. Hereditary severe insulin resistance syndrome: pathogenesis, pathophysiology, and clinical management. Genes Dis. 2023;10:1846\u201356. https:\/\/doi.org\/10.1016\/j.gendis.2022.03.016.","journal-title":"Genes Dis"},{"key":"408_CR7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3390\/nu14040823","volume":"14","author":"E Papakonstantinou","year":"2022","unstructured":"Papakonstantinou E, Oikonomou C, Nychas G, Dimitriadis GD. Effects of diet, lifestyle, chrononutrition and alternative dietary interventions on postprandial glycemia and insulin resistance. Nutrients. 2022;14:823. https:\/\/doi.org\/10.3390\/nu14040823.","journal-title":"Nutrients"},{"key":"408_CR8","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1038\/s42255-025-01349-z","volume":"7","author":"JG Burchfield","year":"2025","unstructured":"Burchfield JG, Diaz-Vegas A, James DE. The insulin signalling network. Nat Metab. 2025;7:1745\u201364. https:\/\/doi.org\/10.1038\/s42255-025-01349-z.","journal-title":"Nat Metab"},{"key":"408_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev-physiol-031622-043133","volume":"85","author":"SM Najjar","year":"2023","unstructured":"Najjar SM, Caprio S, Gastaldelli A. Insulin clearance in health and disease. Annu Rev Physiol. 2023;85:363\u201381. https:\/\/doi.org\/10.1146\/annurev-physiol-031622-043133.","journal-title":"Annu Rev Physiol"},{"key":"408_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/JCI77812","volume":"126","author":"VT Samuel","year":"2016","unstructured":"Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126:12\u201322. https:\/\/doi.org\/10.1172\/JCI77812.","journal-title":"J Clin Invest"},{"key":"408_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cld.2011.03.007","volume":"15","author":"A Siddique","year":"2011","unstructured":"Siddique A, Kowdley KV. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis. 2011;15:281\u201396. https:\/\/doi.org\/10.1016\/j.cld.2011.03.007.","journal-title":"Clin Liver Dis"},{"key":"408_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589\u2013604. https:\/\/doi.org\/10.1038\/s41575-019-0186-y.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"408_CR13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","volume":"164","author":"MR Toh","year":"2023","unstructured":"Toh MR, Wong EYT, Wong SH, Ng AWT, Loo L-H, Chow PK-H, et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology. 2023;164:766\u201382. https:\/\/doi.org\/10.1053\/j.gastro.2023.01.033.","journal-title":"Gastroenterology"},{"key":"408_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.6000\/1929-2279.2018.07.03.1","volume":"7","author":"A Zhong","year":"2018","unstructured":"Zhong A, Chang M, Yu T, Gau R, Riley DJ, Chen Y, et al. Aberrant DNA damage response and DNA repair pathway in high glucose conditions. J Cancer Res Updat. 2018;7:64. https:\/\/doi.org\/10.6000\/1929-2279.2018.07.03.1.","journal-title":"J Cancer Res Updat"},{"key":"408_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00125-009-1558-6","volume":"53","author":"B Draznin","year":"2010","unstructured":"Draznin B. Mitogenic action of insulin: friend, foe or \u2018frenemy\u2019? Diabetologia. 2010;53:229\u201333. https:\/\/doi.org\/10.1007\/s00125-009-1558-6.","journal-title":"Diabetologia"},{"key":"408_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-020-0295-5","volume":"20","author":"EJ Gallagher","year":"2020","unstructured":"Gallagher EJ, LeRoith D. Hyperinsulinaemia in cancer. Nat Rev Cancer. 2020;20:629\u201344. https:\/\/doi.org\/10.1038\/s41568-020-0295-5.","journal-title":"Nat Rev Cancer"},{"key":"408_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/nyas.12395","volume":"1311","author":"C Manrique","year":"2014","unstructured":"Manrique C, Lastra G, Sowers JR. New insights into insulin action and resistance in the vasculature. Ann N Y Acad Sci. 2014;1311:138\u201350. https:\/\/doi.org\/10.1111\/nyas.12395.","journal-title":"Ann N Y Acad Sci"},{"key":"408_CR18","doi-asserted-by":"publisher","first-page":"E766","DOI":"10.1152\/ajpendo.00254.2020","volume":"321","author":"S Kakehi","year":"2021","unstructured":"Kakehi S, Tamura Y, Ikeda S, Kaga N, Taka H, Ueno N, et al. Short-term physical inactivity induces diacylglycerol accumulation and insulin resistance in muscle via lipin1 activation. Am J Physiol-Endocrinol Metab. 2021;321:E766\u201381. https:\/\/doi.org\/10.1152\/ajpendo.00254.2020.","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"408_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1210\/clinem\/dgab647","volume":"107","author":"WV Trim","year":"2022","unstructured":"Trim WV, Walhin J-P, Koumanov F, Bouloumi\u00e9 A, Lindsay MA, Travers RL, et al. The impact of long-term physical inactivity on adipose tissue immunometabolism. J Clin Endocrinol Metab. 2022;107:177\u201391. https:\/\/doi.org\/10.1210\/clinem\/dgab647.","journal-title":"J Clin Endocrinol Metab"},{"key":"408_CR20","doi-asserted-by":"publisher","first-page":"e1402","DOI":"10.1210\/clinem\/dgad653","volume":"109","author":"S Dagogo-Jack","year":"2024","unstructured":"Dagogo-Jack S. Leptin and Insulin Sensitivity: Endogenous Signals of Metabolic Homeostasis. J Clin Endocrinol Metab. 2024;109:e1402\u20133. https:\/\/doi.org\/10.1210\/clinem\/dgad653.","journal-title":"J Clin Endocrinol Metab"},{"key":"408_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.tem.2022.09.002","volume":"33","author":"NR Kerr","year":"2022","unstructured":"Kerr NR, Booth FW. Contributions of physical inactivity and sedentary behavior to metabolic and endocrine diseases. Trends Endocrinol Metab. 2022;33:817\u201327. https:\/\/doi.org\/10.1016\/j.tem.2022.09.002.","journal-title":"Trends Endocrinol Metab"},{"key":"408_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2337\/db22-0612","volume":"72","author":"DP Andersson","year":"2022","unstructured":"Andersson DP, Kerr AG, Dahlman I, Ryd\u00e9n M, Arner P. Relationship between a sedentary lifestyle and adipose insulin resistance. Diabetes. 2022;72:316\u201325. https:\/\/doi.org\/10.2337\/db22-0612.","journal-title":"Diabetes"},{"key":"408_CR23","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1152\/physrev.00022.2022","volume":"103","author":"AJ Pinto","year":"2023","unstructured":"Pinto AJ, Bergouignan A, Dempsey PC, Roschel H, Owen N, Gualano B, et al. Physiology of sedentary behavior. Physiol Rev. 2023;103:2561\u2013622. https:\/\/doi.org\/10.1152\/physrev.00022.2022.","journal-title":"Physiol Rev"},{"key":"408_CR24","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.1152\/ajpendo.00070.2024","volume":"327","author":"B Brayner","year":"2024","unstructured":"Brayner B, Keske MA, Roberts-Thomson KM, Parker L, Betik AC, Thomas HJ, et al. Short-term high-calorie high-fat feeding induces hyperinsulinemia and blunts skeletal muscle microvascular blood flow in healthy humans. Am J Physiol-Endocrinol Metab. 2024;327:E42-54. https:\/\/doi.org\/10.1152\/ajpendo.00070.2024.","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"408_CR25","doi-asserted-by":"publisher","unstructured":"Kullmann S, Wagner L, Hauffe R, K\u00fchnel A, Sandforth L, Veit R, et al. A short-term, high-caloric diet has prolonged effects on brain insulin action in men. Nat Metab. 2025:1\u20139. https:\/\/doi.org\/10.1038\/s42255-025-01226-9.","DOI":"10.1038\/s42255-025-01226-9"},{"key":"408_CR26","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.3390\/nu17203244","volume":"17","author":"H Kashima","year":"2025","unstructured":"Kashima H, Morinaka Y, Endo K, Sugimoto M, Nagao N, Mabuchi R, et al. Regular or irregular breakfast skipping suppresses the vascular endothelial function of the brachial artery. Nutrients. 2025;17:3244. https:\/\/doi.org\/10.3390\/nu17203244.","journal-title":"Nutrients"},{"key":"408_CR27","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1186\/s12967-025-06870-z","volume":"23","author":"X Ren","year":"2025","unstructured":"Ren X, Zhang M, Sun X, Zheng L, Bi Y, Li Q, et al. The role of irregular eating behaviors in metabolic dysfunction-associated steatotic liver disease: evidence from a multicenter cross-sectional study in China. J Transl Med. 2025;23:859. https:\/\/doi.org\/10.1186\/s12967-025-06870-z.","journal-title":"J Transl Med"},{"key":"408_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jadohealth.2020.10.012","volume":"69","author":"P Chen","year":"2021","unstructured":"Chen P, Baylin A, Lee J, Dunietz GL, Cantoral A, Tellez Rojo MM, et al. The association between sleep duration and sleep timing and insulin resistance among adolescents in Mexico City. J Adolesc Health. 2021;69:57\u201363. https:\/\/doi.org\/10.1016\/j.jadohealth.2020.10.012.","journal-title":"J Adolesc Health"},{"key":"408_CR29","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1210\/clinem\/dgad089","volume":"108","author":"X Wang","year":"2023","unstructured":"Wang X, Zhao C, Feng H, Li G, He L, Yang L, et al. Associations of insomnia with insulin resistance traits: a cross-sectional and mendelian randomization study. J Clin Endocrinol Metab. 2023;108:e574\u201382. https:\/\/doi.org\/10.1210\/clinem\/dgad089.","journal-title":"J Clin Endocrinol Metab"},{"key":"408_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41574-018-0122-1","volume":"15","author":"DJ Stenvers","year":"2019","unstructured":"Stenvers DJ, Scheer FA, Schrauwen P, la Fleur SE, Kalsbeek A. Circadian clocks and insulin resistance. Nat Rev Endocrinol. 2019;15:75\u201389. https:\/\/doi.org\/10.1038\/s41574-018-0122-1.","journal-title":"Nat Rev Endocrinol"},{"key":"408_CR31","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/metabo14020126","volume":"14","author":"TK Her","year":"2024","unstructured":"Her TK, Li J, Lin H, Liu D, Root KM, Regal JF, et al. Circadian disruption across lifespan impairs glucose homeostasis and insulin sensitivity in adult mice. Metabolites. 2024;14:126. https:\/\/doi.org\/10.3390\/metabo14020126.","journal-title":"Metabolites"},{"key":"408_CR32","doi-asserted-by":"publisher","first-page":"107011","DOI":"10.1016\/j.phrs.2023.107011","volume":"199","author":"J Hannemann","year":"2024","unstructured":"Hannemann J, Laing A, Middleton B, Schwedhelm E, Marx N, Federici M, et al. Effect of oral melatonin treatment on insulin resistance and diurnal blood pressure variability in night shift workers. A double-blind, randomized, placebo-controlled study. Pharmacol Res. 2024;199:107011. https:\/\/doi.org\/10.1016\/j.phrs.2023.107011.","journal-title":"Pharmacol Res"},{"key":"408_CR33","doi-asserted-by":"publisher","first-page":"e12956","DOI":"10.1111\/jpi.12956","volume":"76","author":"EM Speksnijder","year":"2024","unstructured":"Speksnijder EM, Bisschop PH, Siegelaar SE, Stenvers DJ, Kalsbeek A. Circadian desynchrony and glucose metabolism. J Pineal Res. 2024;76:e12956. https:\/\/doi.org\/10.1111\/jpi.12956.","journal-title":"J Pineal Res"},{"issue":"1","key":"408_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cmet.2024.09.012","volume":"37","author":"K Sakamoto","year":"2025","unstructured":"Sakamoto K, Butera MA, Zhou C, Maurizi G, Chen B, Ling L, et al. Overnutrition causes insulin resistance and metabolic disorder through increased sympathetic nervous system activity. Cell Metab. 2025;37(1):121-137.e6. https:\/\/doi.org\/10.1016\/j.cmet.2024.09.012.","journal-title":"Cell Metab"},{"key":"408_CR35","doi-asserted-by":"publisher","first-page":"12074","DOI":"10.3390\/ijms241512074","volume":"24","author":"C Miro","year":"2023","unstructured":"Miro C, Nappi A, Sagliocchi S, Di Cicco E, Murolo M, Torabinejad S, et al. Thyroid hormone regulates the lipid content of muscle fibers, thus affecting physical exercise performance. Int J Mol Sci. 2023;24:12074. https:\/\/doi.org\/10.3390\/ijms241512074.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"408_CR36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1089\/thy.2021.0351","volume":"32","author":"M Str\u0105czkowski","year":"2022","unstructured":"Str\u0105czkowski M, Niko\u0142ajuk A, Stefanowicz M, Matulewicz N, Fernandez-Real JM, Karczewska-Kupczewska M. Adipose tissue and skeletal muscle expression of genes associated with thyroid hormone action in obesity and insulin resistance. Thyroid. 2022;32(2):206\u201314. https:\/\/doi.org\/10.1089\/thy.2021.0351.","journal-title":"Thyroid"},{"key":"408_CR37","doi-asserted-by":"publisher","first-page":"e3436","DOI":"10.1210\/clinem\/dgab375","volume":"106","author":"PY Liu","year":"2021","unstructured":"Liu PY, Lawrence-Sidebottom D, Piotrowska K, Zhang W, Iranmanesh A, Auchus RJ, et al. Clamping cortisol and testosterone mitigates the development of insulin resistance during sleep restriction in men. J Clin Endocrinol Metab. 2021;106:e3436\u201348. https:\/\/doi.org\/10.1210\/clinem\/dgab375.","journal-title":"J Clin Endocrinol Metab"},{"key":"408_CR38","doi-asserted-by":"publisher","first-page":"E105","DOI":"10.1152\/ajpendo.00070.2021","volume":"321","author":"HE Kunz","year":"2021","unstructured":"Kunz HE, Hart CR, Gries KJ, Parvizi M, Laurenti M, Dalla Man C, et al. Adipose tissue macrophage populations and inflammation are associated with systemic inflammation and insulin resistance in obesity. Am J Physiol-Endocrinol Metab. 2021;321:E105\u201321. https:\/\/doi.org\/10.1152\/ajpendo.00070.2021.","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"408_CR39","doi-asserted-by":"publisher","first-page":"13238","DOI":"10.3390\/ijms252413238","volume":"25","author":"JAMJL Janssen","year":"2024","unstructured":"Janssen JAMJL. The causal role of ectopic fat deposition in the pathogenesis of metabolic syndrome. Int J Mol Sci. 2024;25:13238. https:\/\/doi.org\/10.3390\/ijms252413238.","journal-title":"Int J Mol Sci"},{"key":"408_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/jcm10030390","volume":"10","author":"A London","year":"2021","unstructured":"London A, Lundsgaard A-M, Kiens B, Bojsen-M\u00f8ller KN. The role of hepatic fat accumulation in glucose and insulin homeostasis\u2014dysregulation by the liver. J Clin Med. 2021;10:390. https:\/\/doi.org\/10.3390\/jcm10030390.","journal-title":"J Clin Med"},{"key":"408_CR41","doi-asserted-by":"publisher","first-page":"109221","DOI":"10.1016\/j.isci.2024.109221","volume":"27","author":"L Wang","year":"2024","unstructured":"Wang L, Valencak TG, Shan T. Fat infiltration in skeletal muscle: influential triggers and regulatory mechanism. iScience. 2024;27:109221. https:\/\/doi.org\/10.1016\/j.isci.2024.109221.","journal-title":"iScience"},{"key":"408_CR42","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/jdi.13360","volume":"12","author":"X Kong","year":"2021","unstructured":"Kong X, Yang Z, Zhang B, Chen X, Yu L, Zhu H, et al. Maternal and paternal histories differentially influence risks for diabetes, insulin secretion and insulin resistance in a Chinese population. J Diabetes Investig. 2021;12:434\u201345. https:\/\/doi.org\/10.1111\/jdi.13360.","journal-title":"J Diabetes Investig"},{"key":"408_CR43","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s12916-025-04282-w","volume":"23","author":"L Jurado-Sumariva","year":"2025","unstructured":"Jurado-Sumariva L, Gonz\u00e1lez-Dom\u00ednguez \u00c1, Savolainen O, Dom\u00ednguez-Riscart J, Landberg R, Gonz\u00e1lez-Dom\u00ednguez R. Insulin resistance as a potential driving force of parental obesity-induced adverse metabolic programming mechanisms in children with obesity. BMC Med. 2025;23:458. https:\/\/doi.org\/10.1186\/s12916-025-04282-w.","journal-title":"BMC Med"},{"key":"408_CR44","doi-asserted-by":"publisher","first-page":"e13644","DOI":"10.1111\/obr.13644","volume":"25","author":"J Zhang","year":"2024","unstructured":"Zhang J, Clayton GL, Overvad K, Olsen A, Lawlor DA, Dahm CC. Body mass index in parents and their adult offspring: a systematic review and meta-analysis. Obes Rev. 2024;25:e13644. https:\/\/doi.org\/10.1111\/obr.13644.","journal-title":"Obes Rev"},{"key":"408_CR45","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/s41588-023-01408-9","volume":"55","author":"A Williamson","year":"2023","unstructured":"Williamson A, Norris DM, Yin X, Broadaway KA, Moxley AH, Vadlamudi S, et al. Genome-wide association study and functional characterization identifies candidate genes for insulin-stimulated glucose uptake. Nat Genet. 2023;55:973\u201383. https:\/\/doi.org\/10.1038\/s41588-023-01408-9.","journal-title":"Nat Genet"},{"key":"408_CR46","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s13287-022-03123-4","volume":"13","author":"B Memon","year":"2022","unstructured":"Memon B, Elsayed AK, Bettahi I, Suleiman N, Younis I, Wehedy E, et al. iPSCs derived from insulin resistant offspring of type 2 diabetic patients show increased oxidative stress and lactate secretion. Stem Cell Res Ther. 2022;13:428. https:\/\/doi.org\/10.1186\/s13287-022-03123-4.","journal-title":"Stem Cell Res Ther"},{"key":"408_CR47","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41434-024-00489-3","volume":"31","author":"X Prieur","year":"2024","unstructured":"Prieur X, Cao L. Precision medicine: toward restoring fat with gene therapy in inherited lipodystrophy. Gene Ther. 2024;31:560\u20132. https:\/\/doi.org\/10.1038\/s41434-024-00489-3.","journal-title":"Gene Ther"},{"key":"408_CR48","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1210\/clinem\/dgab430","volume":"106","author":"SJ Winters","year":"2021","unstructured":"Winters SJ. Endocrine dysfunction in patients with myotonic dystrophy. J Clin Endocrinol Metab. 2021;106:2819\u201327. https:\/\/doi.org\/10.1210\/clinem\/dgab430.","journal-title":"J Clin Endocrinol Metab"},{"key":"408_CR49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2337\/dbi20-0041","volume":"70","author":"S Kang","year":"2021","unstructured":"Kang S. Adipose tissue malfunction drives metabolic dysfunction in Alstr\u00f6m syndrome. Diabetes. 2021;70:323\u20135. https:\/\/doi.org\/10.2337\/dbi20-0041.","journal-title":"Diabetes"},{"key":"408_CR50","doi-asserted-by":"publisher","unstructured":"Radi S, Binmahfooz S, Nawar S, Malaikah H. Alstr\u00f6m Syndrome: A Rare Cause of Severe Insulin Resistance. JCEM Case Rep. 2022;1. https:\/\/doi.org\/10.1210\/jcemcr\/luac012.","DOI":"10.1210\/jcemcr\/luac012"},{"key":"408_CR51","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jacl.2022.06.004","volume":"16","author":"I Atallah","year":"2022","unstructured":"Atallah I, McCormick D, Good J-M, Barigou M, Fraga M, Sempoux C, et al. Partial lipodystrophy, severe dyslipidaemia and insulin resistant diabetes as early signs of Werner syndrome. J Clin Lipidol. 2022;16:583\u201390. https:\/\/doi.org\/10.1016\/j.jacl.2022.06.004.","journal-title":"J Clin Lipidol"},{"key":"408_CR52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1210\/er.2017-00073","volume":"38","author":"A Belfiore","year":"2017","unstructured":"Belfiore A, Malaguarnera R, Vella V, Lawrence MC, Sciacca L, Frasca F, et al. Insulin receptor isoforms in physiology and disease: an updated view. Endocr Rev. 2017;38:379\u2013431. https:\/\/doi.org\/10.1210\/er.2017-00073.","journal-title":"Endocr Rev"},{"key":"408_CR53","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41594-022-00750-6","volume":"29","author":"J Li","year":"2022","unstructured":"Li J, Park J, Mayer JP, Webb KJ, Uchikawa E, Wu J, et al. Synergistic activation of the insulin receptor via two distinct sites. Nat Struct Mol Biol. 2022;29:357\u201368. https:\/\/doi.org\/10.1038\/s41594-022-00750-6.","journal-title":"Nat Struct Mol Biol"},{"key":"408_CR54","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.7150\/ijbs.27173","volume":"14","author":"X Huang","year":"2018","unstructured":"Huang X, Liu G, Guo J, Su Z. The PI3K\/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14:1483\u201396. https:\/\/doi.org\/10.7150\/ijbs.27173.","journal-title":"Int J Biol Sci"},{"key":"408_CR55","doi-asserted-by":"publisher","first-page":"a009191","DOI":"10.1101\/cshperspect.a009191","volume":"6","author":"J Boucher","year":"2014","unstructured":"Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6:a009191. https:\/\/doi.org\/10.1101\/cshperspect.a009191.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"408_CR56","doi-asserted-by":"publisher","first-page":"14892","DOI":"10.1038\/ncomms14892","volume":"8","author":"W Cai","year":"2017","unstructured":"Cai W, Sakaguchi M, Kleinridders A, Gonzalez-Del Pino G, Dreyfuss JM, O\u2019Neill BT, et al. Domain-dependent effects of insulin and IGF-1 receptors on signalling and gene expression. Nat Commun. 2017;8:14892. https:\/\/doi.org\/10.1038\/ncomms14892.","journal-title":"Nat Commun"},{"key":"408_CR57","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1111\/febs.16299","volume":"289","author":"Z Liao","year":"2022","unstructured":"Liao Z, Zhang C, Ding L, Moyers JS, Tang JX, Beals JM. Comprehensive insulin receptor phosphorylation dynamics profiled by mass spectrometry. FEBS J. 2022;289:2657\u201371. https:\/\/doi.org\/10.1111\/febs.16299.","journal-title":"FEBS J"},{"key":"408_CR58","doi-asserted-by":"publisher","unstructured":"Lyu K, Zhang D, Song J, Li X, Perry RJ, Samuel VT, et al. Short-term overnutrition induces white adipose tissue insulin resistance through sn-1,2-diacylglycerol\/PKC\u03b5\/insulin receptor Thr1160 phosphorylation. JCI Insight. n.d.;6:e139946. https:\/\/doi.org\/10.1172\/jci.insight.139946.","DOI":"10.1172\/jci.insight.139946"},{"key":"408_CR59","doi-asserted-by":"publisher","first-page":"e1048","DOI":"10.1002\/ctm2.1048","volume":"12","author":"N Gehrke","year":"2022","unstructured":"Gehrke N, Hofmann LJ, Straub BK, R\u00fchle F, Waisman A, Galle PR, et al. Hepatic interleukin-1 receptor type 1 signalling regulates insulin sensitivity in the early phases of nonalcoholic fatty liver disease. Clin Transl Med. 2022;12:e1048. https:\/\/doi.org\/10.1002\/ctm2.1048.","journal-title":"Clin Transl Med"},{"key":"408_CR60","doi-asserted-by":"publisher","first-page":"7553670","DOI":"10.1155\/2022\/7553670","volume":"2022","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Feng L. Thyroid-stimulating hormone inhibits insulin receptor substrate-1 expression and tyrosyl phosphorylation in 3T3-L1 adipocytes by increasing NF-\u03baB DNA-binding activity. Dis Markers. 2022;2022:7553670. https:\/\/doi.org\/10.1155\/2022\/7553670.","journal-title":"Dis Markers"},{"key":"408_CR61","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.2337\/db15-0242","volume":"64","author":"B Ke","year":"2015","unstructured":"Ke B, Zhao Z, Ye X, Gao Z, Manganiello V, Wu B, et al. Inactivation of NF-\u03baB p65 (RelA) in liver improves insulin sensitivity and inhibits cAMP\/PKA pathway. Diabetes. 2015;64:3355\u201362. https:\/\/doi.org\/10.2337\/db15-0242.","journal-title":"Diabetes"},{"key":"408_CR62","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2174\/1566524020666200427102209","volume":"21","author":"I Alipourfard","year":"2021","unstructured":"Alipourfard I, Bakhtiyari S, Gheysarzadeh A, Renzo LD, Lorenzo AD, Mikeladze D, et al. The key role of Akt protein kinase in metabolic-inflammatory pathways cross-talk: TNF-\u03b1 down-regulation and improving of insulin resistance in HepG2 cell line. Curr Mol Med. 2021;21:257\u201364. https:\/\/doi.org\/10.2174\/1566524020666200427102209.","journal-title":"Curr Mol Med"},{"key":"408_CR63","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/nu16020294","volume":"16","author":"J-E Park","year":"2024","unstructured":"Park J-E, Han J-S. Improving the effect of Ferulic acid on inflammation and insulin resistance by regulating the JNK\/ERK and NF-\u03baB pathways in TNF-\u03b1-treated 3T3-L1 adipocytes. Nutrients. 2024;16:294. https:\/\/doi.org\/10.3390\/nu16020294.","journal-title":"Nutrients"},{"key":"408_CR64","doi-asserted-by":"publisher","unstructured":"Rehman K, Akash MSH, Liaqat A, Kamal S, Qadir MI, Rasul A. Role of Interleukin-6 in Development of Insulin Resistance and Type 2 Diabetes Mellitus. Crit Rev Eukaryot Gene Expr. 2017;27. https:\/\/doi.org\/10.1615\/CritRevEukaryotGeneExpr.2017019712.","DOI":"10.1615\/CritRevEukaryotGeneExpr.2017019712"},{"key":"408_CR65","doi-asserted-by":"publisher","first-page":"159","DOI":"10.26402\/jpp.2022.6.04","volume":"74","author":"R Ma","year":"2023","unstructured":"Ma R, Quan L, Aleteng Q-Q-G, Li L, Zhu J, Jiang S. The impact of sitagliptin in palmitic acid-induced insulin resistance in human HepG2 cells through the suppressor of cytokine signaling 3\/phosphoinositide 3-kinase\/protein kinase B pathway. J Physiol Pharmacol. 2023;74:159. https:\/\/doi.org\/10.26402\/jpp.2022.6.04.","journal-title":"J Physiol Pharmacol"},{"key":"408_CR66","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1038\/s41467-022-31126-5","volume":"13","author":"T Huang","year":"2022","unstructured":"Huang T, Song J, Gao J, Cheng J, Xie H, Zhang L, et al. Adipocyte-derived kynurenine promotes obesity and insulin resistance by activating the AhR\/STAT3\/IL-6 signaling. Nat Commun. 2022;13:3489. https:\/\/doi.org\/10.1038\/s41467-022-31126-5.","journal-title":"Nat Commun"},{"key":"408_CR67","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2147\/ITT.S499605","volume":"14","author":"A Berbudi","year":"2025","unstructured":"Berbudi A, Khairani S, Tjahjadi AI. Interplay between insulin resistance and immune dysregulation in type 2 diabetes mellitus: implications for therapeutic interventions. ImmunoTargets Ther. 2025;14:359\u201382. https:\/\/doi.org\/10.2147\/ITT.S499605.","journal-title":"ImmunoTargets Ther"},{"key":"408_CR68","doi-asserted-by":"publisher","first-page":"113499","DOI":"10.1016\/j.intimp.2024.113499","volume":"143","author":"Y Xia","year":"2024","unstructured":"Xia Y, Jin J, Sun Y, Kong X, Shen Z, Yan R, et al. Tirzepatide\u2019s role in targeting adipose tissue macrophages to reduce obesity-related inflammation and improve insulin resistance. Int Immunopharmacol. 2024;143:113499. https:\/\/doi.org\/10.1016\/j.intimp.2024.113499.","journal-title":"Int Immunopharmacol"},{"key":"408_CR69","doi-asserted-by":"publisher","unstructured":"Xu G-X, Wei S, Yu C, Zhao S-Q, Yang W-J, Feng Y-H, et al. Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions. Front Cell Dev Biol. 2023;11. https:\/\/doi.org\/10.3389\/fcell.2023.1199519.","DOI":"10.3389\/fcell.2023.1199519"},{"key":"408_CR70","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/HEP.0000000000000836","volume":"80","author":"H Gao","year":"2024","unstructured":"Gao H, Rocha KC, Jin Z, Kumar D, Zhang D, Wang K, et al. Restoring SRSF3 in Kupffer cells attenuates obesity-related insulin resistance. Hepatology. 2024;80:363\u201375. https:\/\/doi.org\/10.1097\/HEP.0000000000000836.","journal-title":"Hepatology"},{"key":"408_CR71","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1007\/s00125-022-05682-w","volume":"65","author":"R Bergin","year":"2022","unstructured":"Bergin R, Kinlen D, Kedia-Mehta N, Hayes E, Cassidy FC, Cody D, et al. Mucosal-associated invariant T cells are associated with insulin resistance in childhood obesity, and disrupt insulin signalling via IL-17. Diabetologia. 2022;65:1012\u20137. https:\/\/doi.org\/10.1007\/s00125-022-05682-w.","journal-title":"Diabetologia"},{"issue":"2","key":"408_CR72","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00125-020-05335-w","volume":"64","author":"A Houzelle","year":"2021","unstructured":"Houzelle A, J\u00f6rgensen JA, Schaart G, Daemen S, van Polanen N, Fealy CE, et al. Human skeletal muscle mitochondrial dynamics in relation to oxidative capacity and insulin sensitivity. Diabetologia. 2021;64(2):424\u201336. https:\/\/doi.org\/10.1007\/s00125-020-05335-w.","journal-title":"Diabetologia"},{"key":"408_CR73","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/jcsm.12794","volume":"12","author":"H Lee","year":"2021","unstructured":"Lee H, Ha TY, Jung CH, Nirmala FS, Park S, Huh YH, et al. Mitochondrial dysfunction in skeletal muscle contributes to the development of acute insulin resistance in mice. J Cachexia Sarcopenia Muscle. 2021;12:1925\u201339. https:\/\/doi.org\/10.1002\/jcsm.12794.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"408_CR74","doi-asserted-by":"publisher","first-page":"111016","DOI":"10.1016\/j.diabres.2023.111016","volume":"206","author":"S Colosimo","year":"2023","unstructured":"Colosimo S, Mitra SK, Chaudhury T, Marchesini G. Insulin resistance and metabolic flexibility as drivers of liver and cardiac disease in T2DM. Diabetes Res Clin Pract. 2023;206:111016. https:\/\/doi.org\/10.1016\/j.diabres.2023.111016.","journal-title":"Diabetes Res Clin Pract"},{"key":"408_CR75","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s13679-021-00434-0","volume":"10","author":"D Tsilingiris","year":"2021","unstructured":"Tsilingiris D, Tzeravini E, Koliaki C, Dalamaga M, Kokkinos A. The role of mitochondrial adaptation and metabolic flexibility in the pathophysiology of obesity and insulin resistance: an updated overview. Curr Obes Rep. 2021;10:191\u2013213. https:\/\/doi.org\/10.1007\/s13679-021-00434-0.","journal-title":"Curr Obes Rep"},{"key":"408_CR76","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/antiox12030658","volume":"12","author":"K-A Cojocaru","year":"2023","unstructured":"Cojocaru K-A, Luchian I, Goriuc A, Antoci L-M, Ciobanu C-G, Popescu R, et al. Mitochondrial dysfunction, oxidative stress, and therapeutic strategies in diabetes, obesity, and cardiovascular disease. Antioxidants. 2023;12:658. https:\/\/doi.org\/10.3390\/antiox12030658.","journal-title":"Antioxidants"},{"key":"408_CR77","doi-asserted-by":"publisher","first-page":"9352","DOI":"10.3390\/ijms24119352","volume":"24","author":"P Gonz\u00e1lez","year":"2023","unstructured":"Gonz\u00e1lez P, Lozano P, Ros G, Solano F. Hyperglycemia and oxidative stress: an integral, updated and critical overview of their metabolic interconnections. Int J Mol Sci. 2023;24:9352. https:\/\/doi.org\/10.3390\/ijms24119352.","journal-title":"Int J Mol Sci"},{"key":"408_CR78","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/antiox13030312","volume":"13","author":"Y Hong","year":"2024","unstructured":"Hong Y, Boiti A, Vallone D, Foulkes NS. Reactive oxygen species signaling and oxidative stress: transcriptional regulation and evolution. Antioxidants. 2024;13:312. https:\/\/doi.org\/10.3390\/antiox13030312.","journal-title":"Antioxidants"},{"key":"408_CR79","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3109\/10715762.2015.1031662","volume":"49","author":"N Jaiswal","year":"2015","unstructured":"Jaiswal N, Maurya CK, Pandey J, Rai AK, Tamrakar AK. Fructose-induced ROS generation impairs glucose utilization in L6 skeletal muscle cells. Free Radic Res. 2015;49:1055\u201368. https:\/\/doi.org\/10.3109\/10715762.2015.1031662.","journal-title":"Free Radic Res"},{"key":"408_CR80","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3390\/biom12091228","volume":"12","author":"E Mukai","year":"2022","unstructured":"Mukai E, Fujimoto S, Inagaki N. Role of reactive oxygen species in glucose metabolism disorder in diabetic pancreatic \u03b2-cells. Biomolecules. 2022;12:1228. https:\/\/doi.org\/10.3390\/biom12091228.","journal-title":"Biomolecules"},{"key":"408_CR81","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1038\/s41467-019-12523-9","volume":"10","author":"C Henr\u00edquez-Olguin","year":"2019","unstructured":"Henr\u00edquez-Olguin C, Knudsen JR, Raun SH, Li Z, Dalbram E, Treebak JT, et al. Cytosolic ROS production by NADPH oxidase 2 regulates muscle glucose uptake during exercise. Nat Commun. 2019;10:4623. https:\/\/doi.org\/10.1038\/s41467-019-12523-9.","journal-title":"Nat Commun"},{"key":"408_CR82","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1016\/j.molcel.2021.08.018","volume":"81","author":"C Lennicke","year":"2021","unstructured":"Lennicke C, Cochem\u00e9 HM. Redox metabolism: ROS as specific molecular regulators of cell signaling and function. Mol Cell. 2021;81:3691\u2013707. https:\/\/doi.org\/10.1016\/j.molcel.2021.08.018.","journal-title":"Mol Cell"},{"key":"408_CR83","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/hep.32562","volume":"77","author":"A Ajoolabady","year":"2023","unstructured":"Ajoolabady A, Kaplowitz N, Lebeaupin C, Kroemer G, Kaufman RJ, Malhi H, et al. Endoplasmic reticulum stress in liver diseases. Hepatology. 2023;77:619. https:\/\/doi.org\/10.1002\/hep.32562.","journal-title":"Hepatology"},{"key":"408_CR84","doi-asserted-by":"publisher","first-page":"108481","DOI":"10.1016\/j.jnutbio.2020.108481","volume":"88","author":"J Zhang","year":"2021","unstructured":"Zhang J, Yang P, Wang H, Huang Q, Chen T, Li N, et al. N-3 PUFAs inhibited hepatic ER stress induced by feeding of a high-saturated fat diet accompanied by the expression LOX-1. J Nutr Biochem. 2021;88:108481. https:\/\/doi.org\/10.1016\/j.jnutbio.2020.108481.","journal-title":"J Nutr Biochem"},{"key":"408_CR85","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1111\/jcmm.16338","volume":"25","author":"L Li","year":"2021","unstructured":"Li L, Zeng X, Liu Z, Chen X, Li L, Luo R, et al. Mesenchymal stromal cells protect hepatocytes from lipotoxicity through alleviation of endoplasmic reticulum stress by restoring SERCA activity. J Cell Mol Med. 2021;25:2976\u201393. https:\/\/doi.org\/10.1111\/jcmm.16338.","journal-title":"J Cell Mol Med"},{"key":"408_CR86","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41420-022-00910-z","volume":"8","author":"C Yang","year":"2022","unstructured":"Yang C, Wang Z, Hu Y, Yang S, Cheng F, Rao J, et al. Hyperglycemia-triggered ATF6-CHOP pathway aggravates acute inflammatory liver injury by \u03b2-catenin signaling. Cell Death Discov. 2022;8:115. https:\/\/doi.org\/10.1038\/s41420-022-00910-z.","journal-title":"Cell Death Discov"},{"key":"408_CR87","doi-asserted-by":"publisher","first-page":"6895","DOI":"10.3168\/jds.2021-21754","volume":"105","author":"Z Fang","year":"2022","unstructured":"Fang Z, Gao W, Jiang Q, Loor JJ, Zhao C, Du X, et al. Targeting IRE1\u03b1 and PERK in the endoplasmic reticulum stress pathway attenuates fatty acid-induced insulin resistance in bovine hepatocytes. J Dairy Sci. 2022;105:6895\u2013908. https:\/\/doi.org\/10.3168\/jds.2021-21754.","journal-title":"J Dairy Sci"},{"key":"408_CR88","doi-asserted-by":"publisher","first-page":"108445","DOI":"10.1016\/j.envint.2024.108445","volume":"184","author":"H Du","year":"2024","unstructured":"Du H, Li J, Wei X, Yang D, Zhang B, Fan X, et al. Methylparaben induces hepatic glycolipid metabolism disorder by activating the IRE1\u03b1-XBP1 signaling pathway in male mice. Environ Int. 2024;184:108445. https:\/\/doi.org\/10.1016\/j.envint.2024.108445.","journal-title":"Environ Int"},{"key":"408_CR89","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cmet.2010.04.005","volume":"11","author":"L Yang","year":"2010","unstructured":"Yang L, Li P, Fu S, Calay ES, Hotamisligil GS. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 2010;11:467\u201378. https:\/\/doi.org\/10.1016\/j.cmet.2010.04.005.","journal-title":"Cell Metab"},{"key":"408_CR90","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2337\/db11-1652","volume":"62","author":"T Otoda","year":"2013","unstructured":"Otoda T, Takamura T, Misu H, Ota T, Murata S, Hayashi H, et al. Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver. Diabetes. 2013;62:811\u201324. https:\/\/doi.org\/10.2337\/db11-1652.","journal-title":"Diabetes"},{"key":"408_CR91","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1089\/ars.2014.5939","volume":"23","author":"A D\u00edaz-Ruiz","year":"2015","unstructured":"D\u00edaz-Ruiz A, Guzm\u00e1n-Ruiz R, Moreno NR, Garc\u00eda-Rios A, Delgado-Casado N, Membrives A, et al. Proteasome dysfunction associated to oxidative stress and proteotoxicity in adipocytes compromises insulin sensitivity in human obesity. Antioxid Redox Signal. 2015;23:597\u2013612. https:\/\/doi.org\/10.1089\/ars.2014.5939.","journal-title":"Antioxid Redox Signal"},{"key":"408_CR92","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.cmet.2012.03.005","volume":"15","author":"FR Jornayvaz","year":"2012","unstructured":"Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase C\u03b5 and hepatic insulin resistance. Cell Metab. 2012;15:574\u201384. https:\/\/doi.org\/10.1016\/j.cmet.2012.03.005.","journal-title":"Cell Metab"},{"issue":"1","key":"408_CR93","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cmet.2022.11.012","volume":"35","author":"Z-G Zheng","year":"2023","unstructured":"Zheng Z-G, Xu Y-Y, Liu W-P, Zhang Y, Zhang C, Liu H-L, et al. Discovery of a potent allosteric activator of DGKQ that ameliorates obesity-induced insulin resistance via the sn-1,2-DAG-PKC\u03b5 signaling axis. Cell Metab. 2023;35(1):101-117.e11. https:\/\/doi.org\/10.1016\/j.cmet.2022.11.012.","journal-title":"Cell Metab"},{"key":"408_CR94","doi-asserted-by":"publisher","unstructured":"Xu W, Zhang D, Ma Y, Gaspar RC, Kahn M, Nasiri A, et al. Ceramide synthesis inhibitors prevent lipid-induced insulin resistance through the DAG-PKC\u03b5-insulin receptorT1150 phosphorylation pathway. Cell Rep. 2024;43. https:\/\/doi.org\/10.1016\/j.celrep.2024.114746.","DOI":"10.1016\/j.celrep.2024.114746"},{"key":"408_CR95","doi-asserted-by":"publisher","unstructured":"Roszczyc-Owsiejczuk K, Zabielski P. Sphingolipids as a Culprit of Mitochondrial Dysfunction in Insulin Resistance and Type 2 Diabetes. Front Endocrinol. 2021;12. https:\/\/doi.org\/10.3389\/fendo.2021.635175.","DOI":"10.3389\/fendo.2021.635175"},{"key":"408_CR96","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1007\/s00125-024-06280-8","volume":"67","author":"KA Zemski Berry","year":"2024","unstructured":"Zemski Berry KA, Garfield A, Jambal P, Zarini S, Perreault L, Bergman BC. Oxidised phosphatidylcholine induces sarcolemmal ceramide accumulation and insulin resistance in skeletal muscle. Diabetologia. 2024;67:2819\u201332. https:\/\/doi.org\/10.1007\/s00125-024-06280-8.","journal-title":"Diabetologia"},{"key":"408_CR97","doi-asserted-by":"publisher","unstructured":"Serum dihydroceramides correlate with insulin sensitivity in humans and decrease insulin sensitivity in vitro. J Lipid Res. 2022;63:100270. https:\/\/doi.org\/10.1016\/j.jlr.2022.100270.","DOI":"10.1016\/j.jlr.2022.100270"},{"key":"408_CR98","doi-asserted-by":"publisher","first-page":"9178","DOI":"10.1021\/acs.jafc.0c06831","volume":"69","author":"J-Y Yang","year":"2021","unstructured":"Yang J-Y, Zhang T-T, Dong Z, Shi H-H, Xu J, Mao X-Z, et al. Dietary supplementation with exogenous sea-cucumber-derived ceramides and glucosylceramides alleviates insulin resistance in high-fructose-diet-fed rats by upregulating the IRS\/PI3K\/Akt signaling pathway. J Agric Food Chem. 2021;69:9178\u201387. https:\/\/doi.org\/10.1021\/acs.jafc.0c06831.","journal-title":"J Agric Food Chem"},{"key":"408_CR99","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.3390\/ijms23062979","volume":"23","author":"MT Nguyen","year":"2022","unstructured":"Nguyen MT, Min K-H, Lee W. Mir-183-5p induced by saturated fatty acids hinders insulin signaling by downregulating IRS-1 in hepatocytes. Int J Mol Sci. 2022;23:2979. https:\/\/doi.org\/10.3390\/ijms23062979.","journal-title":"Int J Mol Sci"},{"key":"408_CR100","doi-asserted-by":"publisher","first-page":"100756","DOI":"10.1016\/j.jhepr.2023.100756","volume":"5","author":"I Garcia-Martinez","year":"2023","unstructured":"Garcia-Martinez I, Alen R, Pereira L, Povo-Retana A, Astudillo AM, Hitos AB, et al. Saturated fatty acid-enriched small extracellular vesicles mediate a crosstalk inducing liver inflammation and hepatocyte insulin resistance. JHEP Rep. 2023;5:100756. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100756.","journal-title":"JHEP Rep"},{"key":"408_CR101","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/biom12060739","volume":"12","author":"V Saraswathi","year":"2022","unstructured":"Saraswathi V, Kumar N, Ai W, Gopal T, Bhatt S, Harris EN, et al. Myristic acid supplementation aggravates high fat diet-induced adipose inflammation and systemic insulin resistance in mice. Biomolecules. 2022;12:739. https:\/\/doi.org\/10.3390\/biom12060739.","journal-title":"Biomolecules"},{"key":"408_CR102","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41574-023-00809-4","volume":"19","author":"M R\u00e9gnier","year":"2023","unstructured":"R\u00e9gnier M, Carbinatti T, Parlati L, Benhamed F, Postic C. The role of ChREBP in carbohydrate sensing and NAFLD development. Nat Rev Endocrinol. 2023;19:336\u201349. https:\/\/doi.org\/10.1038\/s41574-023-00809-4.","journal-title":"Nat Rev Endocrinol"},{"key":"408_CR103","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/cells11081312","volume":"11","author":"A Twarda-Clapa","year":"2022","unstructured":"Twarda-Clapa A, Olczak A, Bia\u0142kowska AM, Kozio\u0142kiewicz M. Advanced glycation end-products (AGEs): Formation, chemistry, classification, receptors, and diseases related to AGEs. Cells. 2022;11:1312. https:\/\/doi.org\/10.3390\/cells11081312.","journal-title":"Cells"},{"key":"408_CR104","doi-asserted-by":"publisher","first-page":"E279","DOI":"10.1152\/ajpendo.00218.2022","volume":"324","author":"H Du","year":"2023","unstructured":"Du H, Ma Y, Wang X, Zhang Y, Zhu L, Shi S, et al. Advanced glycation end products induce skeletal muscle atrophy and insulin resistance via activating ROS-mediated ER stress PERK\/FOXO1 signaling. Am J Physiol-Endocrinol Metab. 2023;324:E279\u201387. https:\/\/doi.org\/10.1152\/ajpendo.00218.2022.","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"408_CR105","doi-asserted-by":"publisher","first-page":"2200046","DOI":"10.1002\/mnfr.202200046","volume":"66","author":"Y Wu","year":"2022","unstructured":"Wu Y, Zong M, Wu H, He D, Li L, Zhang X, et al. Dietary advanced glycation end-products affects the progression of early diabetes by intervening in carbohydrate and lipid metabolism. Mol Nutr Food Res. 2022;66:2200046. https:\/\/doi.org\/10.1002\/mnfr.202200046.","journal-title":"Mol Nutr Food Res"},{"key":"408_CR106","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13167-025-00410-x","volume":"16","author":"X Chen","year":"2025","unstructured":"Chen X, Balmer L, Lin K, Cao W, Huang Z, Chen X, et al. IgG n-glycosylation contributes to different severities of insulin resistance: implications for 3P medical approaches. EPMA J. 2025;16:419\u201335. https:\/\/doi.org\/10.1007\/s13167-025-00410-x.","journal-title":"EPMA J"},{"key":"408_CR107","doi-asserted-by":"publisher","first-page":"109500","DOI":"10.1016\/j.jnutbio.2023.109500","volume":"123","author":"J Ulke","year":"2024","unstructured":"Ulke J, Schwedler C, Kr\u00fcger J, Stein V, Geserick P, Kleinridders A, et al. High-fat diet alters N-glycosylation of PTPRJ in murine liver. J Nutr Biochem. 2024;123:109500. https:\/\/doi.org\/10.1016\/j.jnutbio.2023.109500.","journal-title":"J Nutr Biochem"},{"key":"408_CR108","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3390\/cells11040705","volume":"11","author":"IO Bolanle","year":"2022","unstructured":"Bolanle IO, Palmer TM. Targeting protein O-GlcNAcylation, a link between type 2 diabetes mellitus and inflammatory disease. Cells. 2022;11:705. https:\/\/doi.org\/10.3390\/cells11040705.","journal-title":"Cells"},{"key":"408_CR109","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/nature06668","volume":"451","author":"X Yang","year":"2008","unstructured":"Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, So WV, et al. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature. 2008;451:964\u20139. https:\/\/doi.org\/10.1038\/nature06668.","journal-title":"Nature"},{"key":"408_CR110","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12929-022-00851-w","volume":"29","author":"T Issad","year":"2022","unstructured":"Issad T, Al-Mukh H, Bouaboud A, Pagesy P. Protein O-GlcNAcylation and the regulation of energy homeostasis: lessons from knock-out mouse models. J Biomed Sci. 2022;29:64. https:\/\/doi.org\/10.1186\/s12929-022-00851-w.","journal-title":"J Biomed Sci"},{"key":"408_CR111","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.biochi.2021.10.017","volume":"193","author":"MT de Souza","year":"2022","unstructured":"de Souza MT, Martins FF, de Macedo Cardoso LE, Aguila MB, Mandarim-de-Lacerda CA. Pancreatic islet cells disarray, apoptosis, and proliferation in obese mice. The role of Semaglutide treatment Biochimie. 2022;193:126\u201336. https:\/\/doi.org\/10.1016\/j.biochi.2021.10.017.","journal-title":"The role of Semaglutide treatment Biochimie"},{"key":"408_CR112","doi-asserted-by":"publisher","unstructured":"Cheruiyot A, Hollister-Lock J, Sullivan B, Pan H, Dreyfuss JM, Bonner-Weir S, et al. Sustained hyperglycemia specifically targets translation of mRNAs for insulin secretion. J Clin Invest. 2024;134. https:\/\/doi.org\/10.1172\/JCI173280.","DOI":"10.1172\/JCI173280"},{"key":"408_CR113","doi-asserted-by":"publisher","unstructured":"Horii T, Kozawa J, Fujita Y, Kawata S, Ozawa H, Ishibashi C, et al. Lipid droplet accumulation in \u03b2 cells in patients with type 2 diabetes is associated with insulin resistance, hyperglycemia and \u03b2 cell dysfunction involving decreased insulin granules. Front Endocrinol. 2022;13. https:\/\/doi.org\/10.3389\/fendo.2022.996716.","DOI":"10.3389\/fendo.2022.996716"},{"key":"408_CR114","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2337\/diab.37.10.1316","volume":"37","author":"CJ Goodner","year":"1988","unstructured":"Goodner CJ, Sweet IR, Harrison HC Jr. Rapid reduction and return of surface insulin receptors after exposure to brief pulses of insulin in perifused rat hepatocytes. Diabetes. 1988;37:1316\u201323. https:\/\/doi.org\/10.2337\/diab.37.10.1316.","journal-title":"Diabetes"},{"key":"408_CR115","doi-asserted-by":"publisher","unstructured":"Bergsten P. Pathophysiology of impaired pulsatile insulin release. Diabetes Metab Res Rev. 2000;16:179\u201391.\u00a0https:\/\/doi.org\/10.1002\/1520-7560(200005\/06)16:3%253C179::AID-DMRR115%253E3.0.CO;2-C.","DOI":"10.1002\/1520-7560(200005\/06)16:3%253C179::AID-DMRR115%253E3.0.CO;2-C"},{"key":"408_CR116","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.mam.2015.01.003","volume":"42","author":"LS Satin","year":"2015","unstructured":"Satin LS, Butler PC, Ha J, Sherman AS. Pulsatile insulin secretion, impaired glucose tolerance and type 2 diabetes. Mol Aspects Med. 2015;42:61\u201377. https:\/\/doi.org\/10.1016\/j.mam.2015.01.003.","journal-title":"Mol Aspects Med"},{"key":"408_CR117","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.2337\/db11-1462","volume":"61","author":"AV Matveyenko","year":"2012","unstructured":"Matveyenko AV, Liuwantara D, Gurlo T, Kirakossian D, Dalla Man C, Cobelli C, et al. Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling. Diabetes. 2012;61:2269\u201379. https:\/\/doi.org\/10.2337\/db11-1462.","journal-title":"Diabetes"},{"key":"408_CR118","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2337\/diabetes.54.6.1649","volume":"54","author":"JJ Meier","year":"2005","unstructured":"Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes. 2005;54:1649\u201356. https:\/\/doi.org\/10.2337\/diabetes.54.6.1649.","journal-title":"Diabetes"},{"key":"408_CR119","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/j.2040-4603.2020.tb00136.x","volume":"10","author":"KE Merz","year":"2020","unstructured":"Merz KE, Thurmond DC. Role of skeletal muscle in insulin resistance and glucose uptake. Compr Physiol. 2020;10:785\u2013809. https:\/\/doi.org\/10.1002\/j.2040-4603.2020.tb00136.x.","journal-title":"Compr Physiol"},{"key":"408_CR120","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1056\/NEJM199001253220403","volume":"322","author":"GI Shulman","year":"1990","unstructured":"Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med. 1990;322:223\u20138. https:\/\/doi.org\/10.1056\/NEJM199001253220403.","journal-title":"N Engl J Med"},{"key":"408_CR121","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.beem.2005.07.003","volume":"19","author":"P Kovacs","year":"2005","unstructured":"Kovacs P, Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab. 2005;19:625\u201335. https:\/\/doi.org\/10.1016\/j.beem.2005.07.003.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"408_CR122","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/jcsm.12901","volume":"13","author":"C Li","year":"2022","unstructured":"Li C, Yu K, Shyh-Chang N, Jiang Z, Liu T, Ma S, et al. Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review. J Cachexia Sarcopenia Muscle. 2022;13:781\u201394. https:\/\/doi.org\/10.1002\/jcsm.12901.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"408_CR123","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jhep.2015.02.031","volume":"63","author":"N Fujiwara","year":"2015","unstructured":"Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015;63:131\u201340. https:\/\/doi.org\/10.1016\/j.jhep.2015.02.031.","journal-title":"J Hepatol"},{"key":"408_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00330-023-10131-2","volume":"34","author":"M Nachit","year":"2024","unstructured":"Nachit M, Dioguardi Burgio M, Abyzov A, Garteiser P, Paradis V, Vilgrain V, et al. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease is associated with heterogeneous pattern of fat infiltration in skeletal muscles. Eur Radiol. 2024;34:1\u201310. https:\/\/doi.org\/10.1007\/s00330-023-10131-2.","journal-title":"Eur Radiol"},{"key":"408_CR125","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.3390\/cancers14215290","volume":"14","author":"P Radu","year":"2022","unstructured":"Radu P, Ebadi M, Montano-Loza AJ, Dufour JF. What is the role of body composition assessment in HCC management? Cancers. 2022;14:5290. https:\/\/doi.org\/10.3390\/cancers14215290.","journal-title":"Cancers"},{"key":"408_CR126","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4093\/dmj.2023.0011","volume":"47","author":"S-M An","year":"2023","unstructured":"An S-M, Cho S-H, Yoon JC. Adipose tissue and metabolic health. Diabetes Metab J. 2023;47:595\u2013611. https:\/\/doi.org\/10.4093\/dmj.2023.0011.","journal-title":"Diabetes Metab J"},{"key":"408_CR127","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.celrep.2019.04.010","volume":"27","author":"A Raajendiran","year":"2019","unstructured":"Raajendiran A, Ooi G, Bayliss J, O\u2019Brien PE, Schittenhelm RB, Clark AK, et al. Identification of metabolically distinct adipocyte progenitor cells in human adipose tissues. Cell Rep. 2019;27:1528\u201340. https:\/\/doi.org\/10.1016\/j.celrep.2019.04.010.","journal-title":"Cell Rep"},{"key":"408_CR128","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cmet.2021.03.019","volume":"33","author":"A Santoro","year":"2021","unstructured":"Santoro A, McGraw TE, Kahn BB. Insulin action in adipocytes, adipose remodeling, and systemic effects. Cell Metab. 2021;33:748\u201357. https:\/\/doi.org\/10.1016\/j.cmet.2021.03.019.","journal-title":"Cell Metab"},{"key":"408_CR129","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1467-789X.2009.00623.x","volume":"11","author":"MM Ibrahim","year":"2010","unstructured":"Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11:11\u20138. https:\/\/doi.org\/10.1111\/j.1467-789X.2009.00623.x.","journal-title":"Obes Rev"},{"key":"408_CR130","doi-asserted-by":"publisher","first-page":"187s","DOI":"10.1002\/j.1550-8528.1995.tb00462.x","volume":"3","author":"Y Matsuzawa","year":"1995","unstructured":"Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Kotani K, Tokunaga K. Pathophysiology and pathogenesis of visceral fat obesity. Obes Res. 1995;3:187s-s194. https:\/\/doi.org\/10.1002\/j.1550-8528.1995.tb00462.x.","journal-title":"Obes Res"},{"key":"408_CR131","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.cyto.2013.09.009","volume":"64","author":"J Zhao","year":"2013","unstructured":"Zhao J, Lawless MW. Stop feeding cancer: pro-inflammatory role of visceral adiposity in liver cancer. Cytokine. 2013;64:626\u201337. https:\/\/doi.org\/10.1016\/j.cyto.2013.09.009.","journal-title":"Cytokine"},{"key":"408_CR132","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/liv.15377","volume":"42","author":"C Saponaro","year":"2022","unstructured":"Saponaro C, Sabatini S, Gaggini M, Carli F, Rosso C, Positano V, et al. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals. Liver Int. 2022;42:2418\u201327. https:\/\/doi.org\/10.1111\/liv.15377.","journal-title":"Liver Int"},{"key":"408_CR133","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.cmet.2008.04.004","volume":"7","author":"TT Tran","year":"2008","unstructured":"Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab. 2008;7:410\u201320. https:\/\/doi.org\/10.1016\/j.cmet.2008.04.004.","journal-title":"Cell Metab"},{"key":"408_CR134","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00125-015-3583-y","volume":"58","author":"SL Hocking","year":"2015","unstructured":"Hocking SL, Stewart RL, Brandon AE, Suryana E, Stuart E, Baldwin EM, et al. Subcutaneous fat transplantation alleviates diet-induced glucose intolerance and inflammation in mice. Diabetologia. 2015;58:1587\u2013600.","journal-title":"Diabetologia"},{"key":"408_CR135","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","volume":"36","author":"T Bo","year":"2024","unstructured":"Bo T, Gao L, Yao Z, Shao S, Wang X, Proud CG, et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metab. 2024;36:947\u201368.","journal-title":"Cell Metab"},{"key":"408_CR136","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","volume":"130","author":"GI Smith","year":"2020","unstructured":"Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;130:1453\u201360.","journal-title":"J Clin Invest"},{"key":"408_CR137","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1042\/BCJ20210071","volume":"478","author":"P Ferr\u00e9","year":"2021","unstructured":"Ferr\u00e9 P, Phan F, Foufelle F. SREBP-1c and lipogenesis in the liver: an update. Biochem J. 2021;478:3723\u201339.","journal-title":"Biochem J"},{"key":"408_CR138","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s42255-023-00896-7","volume":"5","author":"Z Yao","year":"2023","unstructured":"Yao Z, Gong Y, Chen W, Shao S, Song Y, Guo H, et al. Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice. Nat Metab. 2023;5:1706\u201325. https:\/\/doi.org\/10.1038\/s42255-023-00896-7.","journal-title":"Nat Metab"},{"key":"408_CR139","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/BF00400466","volume":"37","author":"S Del Prato","year":"1994","unstructured":"Del Prato S, Leonetti F, Simonson D, Sheehan P, Matsuda M, DeFronzo R. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37:1025\u201335. https:\/\/doi.org\/10.1007\/BF00400466.","journal-title":"Diabetologia"},{"key":"408_CR140","doi-asserted-by":"publisher","first-page":"12587","DOI":"10.1073\/pnas.0705408104","volume":"104","author":"KF Petersen","year":"2007","unstructured":"Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci. 2007;104:12587\u201394.","journal-title":"Proc Natl Acad Sci"},{"key":"408_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101238","volume":"50","author":"J Heeren","year":"2021","unstructured":"Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50:101238. https:\/\/doi.org\/10.1016\/j.molmet.2021.101238.","journal-title":"Mol Metab"},{"key":"408_CR142","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.cell.2015.01.012","volume":"160","author":"RJ Perry","year":"2015","unstructured":"Perry RJ, Camporez J-PG, Kursawe R, Titchenell PM, Zhang D, Perry CJ, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015;160:745\u201358.","journal-title":"Cell"},{"key":"408_CR143","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1172\/JCI118742","volume":"97","author":"M Roden","year":"1996","unstructured":"Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996;97:2859\u201365. https:\/\/doi.org\/10.1172\/JCI118742.","journal-title":"J Clin Invest"},{"key":"408_CR144","doi-asserted-by":"publisher","first-page":"3941898","DOI":"10.1155\/2017\/3941898","volume":"2017","author":"G Barrientos","year":"2017","unstructured":"Barrientos G, S\u00e1nchez-Aguilera P, Jaimovich E, Hidalgo C, Llanos P. Membrane cholesterol in skeletal muscle: a novel player in excitation-contraction coupling and insulin resistance. J Diabetes Res. 2017;2017:3941898. https:\/\/doi.org\/10.1155\/2017\/3941898.","journal-title":"J Diabetes Res"},{"key":"408_CR145","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrendo.2017.56","volume":"13","author":"RC Meex","year":"2017","unstructured":"Meex RC, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13:509\u201320. https:\/\/doi.org\/10.1038\/nrendo.2017.56.","journal-title":"Nat Rev Endocrinol"},{"key":"408_CR146","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1007\/s00125-021-05435-1","volume":"64","author":"F Gerst","year":"2021","unstructured":"Gerst F, Kemter E, Lorza-Gil E, Kaiser G, Fritz A-K, Nano R, et al. The hepatokine fetuin-A disrupts functional maturation of pancreatic beta cells. Diabetologia. 2021;64:1358\u201374. https:\/\/doi.org\/10.1007\/s00125-021-05435-1.","journal-title":"Diabetologia"},{"key":"408_CR147","doi-asserted-by":"publisher","first-page":"103333","DOI":"10.1016\/j.redox.2024.103333","volume":"76","author":"D Zhou","year":"2024","unstructured":"Zhou D, Shi Y, Zhang D, Zuo J, Zeng C, Mamtawla G, et al. Liver-secreted FGF21 induces sarcopenia by inhibiting satellite cell myogenesis via klotho beta in decompensated cirrhosis. Redox Biol. 2024;76:103333. https:\/\/doi.org\/10.1016\/j.redox.2024.103333.","journal-title":"Redox Biol"},{"key":"408_CR148","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1097-2765(05)00015-8","volume":"6","author":"MD Michael","year":"2000","unstructured":"Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6:87\u201397. https:\/\/doi.org\/10.1016\/S1097-2765(05)00015-8.","journal-title":"Mol Cell"},{"key":"408_CR149","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1210\/jcem.77.5.8077319","volume":"77","author":"MR Letiexhe","year":"1993","unstructured":"Letiexhe MR, Scheen AJ, Gerard P, Bastens BH, Pirotte J, Belaiche J, et al. Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients. J Clin Endocrinol Metab. 1993;77:1263\u20138. https:\/\/doi.org\/10.1210\/jcem.77.5.8077319.","journal-title":"J Clin Endocrinol Metab"},{"key":"408_CR150","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.3390\/ijms21144860","volume":"21","author":"M Mannelli","year":"2020","unstructured":"Mannelli M, Gamberi T, Magherini F, Fiaschi T. The adipokines in cancer cachexia. Int J Mol Sci. 2020;21:4860. https:\/\/doi.org\/10.3390\/ijms21144860.","journal-title":"Int J Mol Sci"},{"key":"408_CR151","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41577-024-01103-8","volume":"25","author":"H Tilg","year":"2025","unstructured":"Tilg H, Ianiro G, Gasbarrini A, Adolph TE. Adipokines: masterminds of metabolic inflammation. Nat Rev Immunol. 2025;25:250\u201365. https:\/\/doi.org\/10.1038\/s41577-024-01103-8.","journal-title":"Nat Rev Immunol"},{"key":"408_CR152","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s13340-022-00616-8","volume":"14","author":"Y Imi","year":"2023","unstructured":"Imi Y, Ogawa W, Hosooka T. Insulin resistance in adipose tissue and metabolic diseases. Diabetol Int. 2023;14:119\u201324. https:\/\/doi.org\/10.1007\/s13340-022-00616-8.","journal-title":"Diabetol Int"},{"key":"408_CR153","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/372425a0","volume":"372","author":"Y Zhang","year":"1994","unstructured":"Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425\u201332. https:\/\/doi.org\/10.1038\/372425a0.","journal-title":"Nature"},{"key":"408_CR154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07651-1","volume":"20","author":"L Zhang","year":"2020","unstructured":"Zhang L, Yuan Q, Li M, Chai D, Deng W, Wang W. The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis. BMC Cancer. 2020;20:1\u201320. https:\/\/doi.org\/10.1186\/s12885-020-07651-1.","journal-title":"BMC Cancer"},{"key":"408_CR155","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/jcp.2005.035477","volume":"59","author":"S-N Wang","year":"2006","unstructured":"Wang S-N, Yeh Y-T, Yang S-F, Chai C-Y, Lee K-T. Potential role of leptin expression in hepatocellular carcinoma. J Clin Pathol. 2006;59:930\u20134. https:\/\/doi.org\/10.1136\/jcp.2005.035477.","journal-title":"J Clin Pathol"},{"key":"408_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-020-01641-w","volume":"21","author":"H Huang","year":"2021","unstructured":"Huang H, Zhang J, Ling F, Huang Y, Yang M, Zhang Y, et al. Leptin receptor (LEPR) promotes proliferation, migration, and invasion and inhibits apoptosis in hepatocellular carcinoma by regulating ANXA7. Cancer Cell Int. 2021;21:1\u20139. https:\/\/doi.org\/10.1186\/s12935-020-01641-w.","journal-title":"Cancer Cell Int"},{"key":"408_CR157","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000539909","volume":"14","author":"C-L Chen","year":"2024","unstructured":"Chen C-L, Yang W-S, Yang H-I, Chen C-F, Wang L-Y, Lu S-N, et al. Plasma adiponectin levels in relation to chronic hepatitis B infection progression to liver cancer milestones: a prospective study. Liver Cancer. 2024;14:19\u201335. https:\/\/doi.org\/10.1159\/000539909.","journal-title":"Liver Cancer"},{"key":"408_CR158","doi-asserted-by":"publisher","first-page":"0326","DOI":"10.34133\/research.0326","volume":"7","author":"H-M Yang","year":"2024","unstructured":"Yang H-M, Kim J, Kim B-K, Seo HJ, Kim J-Y, Lee J-E, et al. Resistin regulates inflammation and insulin resistance in humans via the endocannabinoid system. Research. 2024;7:0326. https:\/\/doi.org\/10.34133\/research.0326.","journal-title":"Research"},{"key":"408_CR159","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.3748\/wjg.v29.i27.4271","volume":"29","author":"MMI Abdalla","year":"2023","unstructured":"Abdalla MMI. Serum resistin and the risk for hepatocellular carcinoma in diabetic patients. World J Gastroenterol. 2023;29:4271\u201388. https:\/\/doi.org\/10.3748\/wjg.v29.i27.4271.","journal-title":"World J Gastroenterol"},{"key":"408_CR160","doi-asserted-by":"publisher","first-page":"e43401","DOI":"10.7759\/cureus.43401","volume":"15","author":"C Mund","year":"2023","unstructured":"Mund C, Kellellu CK, Rattan R, Mahapatra S, Lamare AA, Jena S. Study of serum apelin and insulin resistance in type 2 diabetes mellitus patients with or without obesity. Cureus. 2023;15:e43401. https:\/\/doi.org\/10.7759\/cureus.43401.","journal-title":"Cureus"},{"key":"408_CR161","doi-asserted-by":"publisher","first-page":"e70152","DOI":"10.1111\/jcmm.70152","volume":"28","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Zhang P, Huo X, Ling Y, Lv X, Lin S, et al. Single-cell and spatial transcriptomics reveal apelin\/APJ pathway\u2019s role in microvessel formation and tumour progression in hepatocellular carcinoma. J Cell Mol Med. 2024;28:e70152. https:\/\/doi.org\/10.1111\/jcmm.70152.","journal-title":"J Cell Mol Med"},{"key":"408_CR162","doi-asserted-by":"publisher","first-page":"112002","DOI":"10.1016\/j.biopha.2021.112002","volume":"142","author":"SA Jaberi","year":"2021","unstructured":"Jaberi SA, Cohen A, D\u2019Souza C, Abdulrazzaq YM, Ojha S, Bastaki S, et al. Lipocalin-2: structure, function, distribution and role in metabolic disorders. Biomed Pharmacother. 2021;142:112002. https:\/\/doi.org\/10.1016\/j.biopha.2021.112002.","journal-title":"Biomed Pharmacother"},{"key":"408_CR163","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1016\/j.apsb.2023.04.010","volume":"13","author":"P Shen","year":"2023","unstructured":"Shen P, Jia Y, Zhou W, Zheng W, Wu Y, Qu S, et al. A biomimetic liver cancer on-a-chip reveals a critical role of LIPOCALIN-2 in promoting hepatocellular carcinoma progression. Acta Pharm Sin B. 2023;13:4621\u201337. https:\/\/doi.org\/10.1016\/j.apsb.2023.04.010.","journal-title":"Acta Pharm Sin B"},{"key":"408_CR164","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1111\/liv.15059","volume":"41","author":"SA Willis","year":"2021","unstructured":"Willis SA, Bawden SJ, Malaikah S, Sargeant JA, Stensel DJ, Aithal GP, et al. The role of hepatic lipid composition in obesity-related metabolic disease. Liver Int. 2021;41:2819\u201335. https:\/\/doi.org\/10.1111\/liv.15059.","journal-title":"Liver Int"},{"key":"408_CR165","doi-asserted-by":"publisher","first-page":"e05702","DOI":"10.1002\/advs.202505702","volume":"12","author":"X Jin","year":"2025","unstructured":"Jin X, Hong Y, Zhao Y, Shi W, Liu R, You X, et al. ZDHHC12 palmitoylates HDAC8 to promote the progression of hepatocellular carcinoma associated with a diet high in saturated fatty acids. Adv Sci. 2025;12:e05702. https:\/\/doi.org\/10.1002\/advs.202505702.","journal-title":"Adv Sci"},{"key":"408_CR166","doi-asserted-by":"publisher","first-page":"8117","DOI":"10.1158\/0008-5472.CAN-09-3871","volume":"70","author":"E Rysman","year":"2010","unstructured":"Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010;70:8117\u201326. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3871.","journal-title":"Cancer Res"},{"key":"408_CR167","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/0008-5472.CAN-20-2199","volume":"81","author":"JD Greenlee","year":"2021","unstructured":"Greenlee JD, Subramanian T, Liu K, King MR. Rafting down the metastatic cascade: the role of lipid rafts in cancer metastasis, cell death, and clinical outcomes. Cancer Res. 2021;81:5\u201317. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-2199.","journal-title":"Cancer Res"},{"key":"408_CR168","doi-asserted-by":"publisher","first-page":"151242","DOI":"10.1016\/j.bbrc.2024.151242","volume":"745","author":"A Uchiyama","year":"2025","unstructured":"Uchiyama A, Kon K, Morinaga M, Fukada H, Yaginuma R, Fukuhara K, et al. Palmitic acid induces insulin resistance and oxidative stress-mediated cell injury through accumulation of lipid rafts in murine hepatocytes. Biochem Biophys Res Commun. 2025;745:151242. https:\/\/doi.org\/10.1016\/j.bbrc.2024.151242.","journal-title":"Biochem Biophys Res Commun"},{"key":"408_CR169","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1021\/bi100882y","volume":"49","author":"I Levental","year":"2010","unstructured":"Levental I, Grzybek M, Simons K. Greasing their way: lipid modifications determine protein association with membrane rafts. Biochemistry. 2010;49:6305\u201316. https:\/\/doi.org\/10.1021\/bi100882y.","journal-title":"Biochemistry"},{"key":"408_CR170","doi-asserted-by":"publisher","first-page":"e13167","DOI":"10.1111\/cpr.13167","volume":"55","author":"B Li","year":"2022","unstructured":"Li B, Qin Y, Yu X, Xu X, Yu W. Lipid raft involvement in signal transduction in cancer cell survival, cell death and metastasis. Cell Prolif. 2022;55:e13167. https:\/\/doi.org\/10.1111\/cpr.13167.","journal-title":"Cell Prolif"},{"key":"408_CR171","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1096\/fj.02-0752rev","volume":"17","author":"MS Cooke","year":"2003","unstructured":"Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003;17:1195\u2013214. https:\/\/doi.org\/10.1096\/fj.02-0752rev.","journal-title":"FASEB J"},{"key":"408_CR172","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1080\/09553002.2021.2003464","volume":"98","author":"AM Fleming","year":"2022","unstructured":"Fleming AM, Burrows CJ. Chemistry of ROS-mediated oxidation to the guanine base in DNA and its biological consequences. Int J Radiat Biol. 2022;98:452\u201360. https:\/\/doi.org\/10.1080\/09553002.2021.2003464.","journal-title":"Int J Radiat Biol"},{"key":"408_CR173","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00204-023-03476-6","volume":"97","author":"B Wang","year":"2023","unstructured":"Wang B, Wang Y, Zhang J, Hu C, Jiang J, Li Y, et al. Ros-induced lipid peroxidation modulates cell death outcome: mechanisms behind apoptosis, autophagy, and ferroptosis. Arch Toxicol. 2023;97:1439\u201351. https:\/\/doi.org\/10.1007\/s00204-023-03476-6.","journal-title":"Arch Toxicol"},{"key":"408_CR174","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3934\/genet.2017.2.103","volume":"4","author":"F Gentile","year":"2017","unstructured":"Gentile F, Arcaro A, Pizzimenti S, Daga M, Cetrangolo GP, Dianzani C, et al. DNA damage by lipid peroxidation products: Implications in cancer, inflammation and autoimmunity. AIMS Genet. 2017;4:103\u201337. https:\/\/doi.org\/10.3934\/genet.2017.2.103.","journal-title":"AIMS Genet"},{"key":"408_CR175","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/carcin\/16.1.93","volume":"16","author":"M Benamira","year":"1995","unstructured":"Benamira M, Johnson K, Chaudhary A, Bruner K, Tibbetts C, Marnett LJ. Induction of mutations by replication of malondialdehyde modified M13 DNA in Escherichia coil: determination of the extent of DNA modification, genetic requirements for mutagenesis, and types of mutations induced. Carcinogenesis. 1995;16:93\u20139. https:\/\/doi.org\/10.1093\/carcin\/16.1.93.","journal-title":"Carcinogenesis"},{"key":"408_CR176","doi-asserted-by":"publisher","first-page":"12379","DOI":"10.1074\/jbc.M111.329623","volume":"287","author":"H-T Wang","year":"2012","unstructured":"Wang H-T, Hu Y, Tong D, Huang J, Gu L, Wu X-R, et al. Effect of carcinogenic acrolein on DNA repair and mutagenic susceptibility. J Biol Chem. 2012;287:12379\u201386. https:\/\/doi.org\/10.1074\/jbc.M111.329623.","journal-title":"J Biol Chem"},{"key":"408_CR177","doi-asserted-by":"publisher","unstructured":"Islam BU, Moinuddin, Mahmood R, Ali A. Genotoxicity and immunogenicity of crotonaldehyde modified human DNA. Int J Biol Macromol. 2014;65:471\u20138. https:\/\/doi.org\/10.1016\/j.ijbiomac.2014.01.065.","DOI":"10.1016\/j.ijbiomac.2014.01.065"},{"key":"408_CR178","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1093\/carcin\/23.11.1781","volume":"23","author":"W Hu","year":"2002","unstructured":"Hu W, Feng Z, Eveleigh J, Iyer G, Pan J, Amin S, et al. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis. 2002;23:1781\u20139. https:\/\/doi.org\/10.1093\/carcin\/23.11.1781.","journal-title":"Carcinogenesis"},{"key":"408_CR179","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1021\/tx200084d","volume":"24","author":"NJ Pillon","year":"2011","unstructured":"Pillon NJ, Vella RE, Soul\u00e8re L, Becchi M, Lagarde M, Soulage CO. Structural and functional changes in human insulin induced by the lipid peroxidation byproducts 4-hydroxy-2-nonenal and 4-hydroxy-2-hexenal. Chem Res Toxicol. 2011;24:752\u201362. https:\/\/doi.org\/10.1021\/tx200084d.","journal-title":"Chem Res Toxicol"},{"key":"408_CR180","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3892\/ijo.2017.3844","volume":"50","author":"C-C Lu","year":"2017","unstructured":"Lu C-C, Chu P-Y, Hsia S-M, Wu C-H, Tung Y-T, Yen G-C. Insulin induction instigates cell proliferation and metastasis in human colorectal cancer cells. Int J Oncol. 2017;50:736\u201344. https:\/\/doi.org\/10.3892\/ijo.2017.3844.","journal-title":"Int J Oncol"},{"key":"408_CR181","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1210\/en.2007-1557","volume":"149","author":"JL Beith","year":"2008","unstructured":"Beith JL, Alejandro EU, Johnson JD. Insulin stimulates primary \u03b2-cell proliferation via Raf-1 kinase. Endocrinology. 2008;149:2251\u201360. https:\/\/doi.org\/10.1210\/en.2007-1557.","journal-title":"Endocrinology"},{"key":"408_CR182","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/0024-3205(81)90482-3","volume":"29","author":"DS Straus","year":"1981","unstructured":"Straus DS. Effects of insulin on cellular growth and proliferation. Life Sci. 1981;29:2131\u20139. https:\/\/doi.org\/10.1016\/0024-3205(81)90482-3.","journal-title":"Life Sci"},{"key":"408_CR183","doi-asserted-by":"publisher","first-page":"5862","DOI":"10.1210\/en.2004-0199","volume":"145","author":"Y Kaburagi","year":"2004","unstructured":"Kaburagi Y, Yamashita R, Ito Y, Okochi H, Yamamoto-Honda R, Yasuda K, et al. Insulin-induced cell cycle progression is impaired in Chinese hamster ovary cells overexpressing insulin receptor substrate-3. Endocrinology. 2004;145:5862\u201374.","journal-title":"Endocrinology"},{"key":"408_CR184","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1042\/BJ20130490","volume":"457","author":"AM Svendsen","year":"2014","unstructured":"Svendsen AM, Winge SB, Zimmermann M, Lindvig AB, Warzecha CB, Sajid W, et al. Down-regulation of cyclin G2 by insulin, IGF-I (insulin-like growth factor 1) and X10 (AspB10 insulin): role in mitogenesis. Biochem J. 2014;457:69\u201377. https:\/\/doi.org\/10.1042\/BJ20130490.","journal-title":"Biochem J"},{"key":"408_CR185","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1080\/15384101.2016.1243189","volume":"15","author":"M Zimmermann","year":"2016","unstructured":"Zimmermann M, Arachchige-Don AP, Donaldson MS, Patriarchi T, Horne MC. Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival. Cell Cycle. 2016;15:3278\u201395. https:\/\/doi.org\/10.1080\/15384101.2016.1243189.","journal-title":"Cell Cycle"},{"key":"408_CR186","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153\u201366. https:\/\/doi.org\/10.1038\/nrc2602.","journal-title":"Nat Rev Cancer"},{"key":"408_CR187","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","volume":"149","author":"J Zucman-Rossi","year":"2015","unstructured":"Zucman-Rossi J, Villanueva A, Nault J-C, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149:1226\u201339. https:\/\/doi.org\/10.1053\/j.gastro.2015.05.061.","journal-title":"Gastroenterology"},{"key":"408_CR188","doi-asserted-by":"publisher","first-page":"7623","DOI":"10.1073\/pnas.1700996114","volume":"114","author":"E Valentino","year":"2017","unstructured":"Valentino E, Bellazzo A, Di Minin G, Sicari D, Apollonio M, Scognamiglio G, et al. Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP. Proc Natl Acad Sci U S A. 2017;114:7623\u20138. https:\/\/doi.org\/10.1073\/pnas.1700996114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"408_CR189","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.18632\/oncotarget.27645","volume":"11","author":"R Sarfstein","year":"2020","unstructured":"Sarfstein R, Werner H. Tumor suppressor p53 regulates insulin receptor (INSR) gene expression via direct binding to the INSR promoter. Oncotarget. 2020;11:2424.","journal-title":"Oncotarget"},{"key":"408_CR190","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse R, Clevers H. Wnt\/\u03b2-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985\u201399. https:\/\/doi.org\/10.1016\/j.cell.2017.05.016.","journal-title":"Cell"},{"key":"408_CR191","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.bbrc.2020.03.147","volume":"526","author":"Z Lei","year":"2020","unstructured":"Lei Z, Yang L, Yang Y, Yang J, Niu Z, Zhang X, et al. Activation of Wnt\/\u03b2-catenin pathway causes insulin resistance and increases lipogenesis in HepG2 cells via regulation of endoplasmic reticulum stress. Biochem Biophys Res Commun. 2020;526:764\u201371. https:\/\/doi.org\/10.1016\/j.bbrc.2020.03.147.","journal-title":"Biochem Biophys Res Commun"},{"key":"408_CR192","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1126\/science.1109083","volume":"308","author":"MA Essers","year":"2005","unstructured":"Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, Korswagen HC. Functional interaction between \u00df-catenin and FOXO in oxidative stress signaling. Science. 2005;308:1181\u20134. https:\/\/doi.org\/10.1126\/science.1109083.","journal-title":"Science"},{"key":"408_CR193","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.tem.2005.03.010","volume":"16","author":"A Barthel","year":"2005","unstructured":"Barthel A, Schmoll D, Unterman TG. Foxo proteins in insulin action and metabolism. Trends Endocrinol Metab. 2005;16:183\u20139. https:\/\/doi.org\/10.1016\/j.tem.2005.03.010.","journal-title":"Trends Endocrinol Metab"},{"key":"408_CR194","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3390\/ijms19103279","volume":"19","author":"D-H Bach","year":"2018","unstructured":"Bach D-H, Long NP, Luu T-T-T, Anh NH, Kwon SW, Lee SK. The dominant role of Forkhead box proteins in cancer. Int J Mol Sci. 2018;19:3279. https:\/\/doi.org\/10.3390\/ijms19103279.","journal-title":"Int J Mol Sci"},{"key":"408_CR195","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41574-020-0329-9","volume":"16","author":"BD Hopkins","year":"2020","unstructured":"Hopkins BD, Goncalves MD, Cantley LC. Insulin\u2013PI3K signalling: an evolutionarily insulated metabolic driver of cancer. Nat Rev Endocrinol. 2020;16:276\u201383. https:\/\/doi.org\/10.1038\/s41574-020-0329-9.","journal-title":"Nat Rev Endocrinol"},{"key":"408_CR196","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606\u201319. https:\/\/doi.org\/10.1038\/nrg1879.","journal-title":"Nat Rev Genet"},{"key":"408_CR197","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1002\/hep.24232","volume":"53","author":"KM Sze","year":"2011","unstructured":"Sze KM, Wong KL, Chu GK, Lee JM, Yau T, Oi-Lin Ng I. Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT\/Sp-1 transcription factor\/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology. 2011;53:1558\u201369. https:\/\/doi.org\/10.1002\/hep.24232.","journal-title":"Hepatology"},{"key":"408_CR198","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1172\/JCI20513","volume":"113","author":"Y Horie","year":"2004","unstructured":"Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004;113:1774\u201383. https:\/\/doi.org\/10.1172\/JCI20513.","journal-title":"J Clin Invest"},{"key":"408_CR199","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.3390\/cancers13205059","volume":"13","author":"M Dillon","year":"2021","unstructured":"Dillon M, Lopez A, Lin E, Sales D, Perets R, Jain P. Progress on Ras\/MAPK signaling research and targeting in blood and solid cancers. Cancers. 2021;13:5059. https:\/\/doi.org\/10.3390\/cancers13205059.","journal-title":"Cancers"},{"key":"408_CR200","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.3390\/cancers13123026","volume":"13","author":"H Moon","year":"2021","unstructured":"Moon H, Ro SW. MAPK\/ERK signaling pathway in hepatocellular carcinoma. Cancers. 2021;13:3026. https:\/\/doi.org\/10.3390\/cancers13123026.","journal-title":"Cancers"},{"key":"408_CR201","doi-asserted-by":"publisher","first-page":"e2019474118","DOI":"10.1073\/pnas.2019474118","volume":"118","author":"H Nagao","year":"2021","unstructured":"Nagao H, Cai W, Wewer Albrechtsen NJ, Steger M, Batista TM, Pan H, et al. Distinct signaling by insulin and IGF-1 receptors and their extra- and intracellular domains. Proc Natl Acad Sci U S A. 2021;118:e2019474118. https:\/\/doi.org\/10.1073\/pnas.2019474118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"408_CR202","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1053\/j.gastro.2016.09.001","volume":"151","author":"I Martinez-Quetglas","year":"2016","unstructured":"Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, et al. IGF2 is up-regulated by epigenetic mechanisms in hepatocellular carcinomas and is an actionable oncogene product in experimental models. Gastroenterology. 2016;151:1192\u2013205. https:\/\/doi.org\/10.1053\/j.gastro.2016.09.001.","journal-title":"Gastroenterology"},{"key":"408_CR203","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s41598-025-85350-2","volume":"15","author":"SM Heckl","year":"2025","unstructured":"Heckl SM, Schneider C, Kercher L, Behrens H-M, Gundlach J-P, Bernsmeier A, et al. Worse survival of hepatocellular cancer patients with membranous insulin receptor overexpression. Sci Rep. 2025;15:1209. https:\/\/doi.org\/10.1038\/s41598-025-85350-2.","journal-title":"Sci Rep"},{"key":"408_CR204","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.canlet.2019.02.037","volume":"450","author":"E Benabou","year":"2019","unstructured":"Benabou E, Salam\u00e9 Z, Wendum D, Lequoy M, Tahraoui S, Merabtene F, et al. Insulin receptor isoform A favors tumor progression in human hepatocellular carcinoma by increasing stem\/progenitor cell features. Cancer Lett. 2019;450:155\u201368. https:\/\/doi.org\/10.1016\/j.canlet.2019.02.037.","journal-title":"Cancer Lett"},{"key":"408_CR205","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1038\/s41467-024-46990-6","volume":"15","author":"W An","year":"2024","unstructured":"An W, Hall C, Li J, Hung A, Wu J, Park J, et al. Activation of the insulin receptor by insulin-like growth factor 2. Nat Commun. 2024;15:2609. https:\/\/doi.org\/10.1038\/s41467-024-46990-6.","journal-title":"Nat Commun"},{"key":"408_CR206","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-021-00245-5","volume":"6","author":"S Khurshid","year":"2022","unstructured":"Khurshid S, Montes M, Comiskey DF, Shane B, Matsa E, Jung F, et al. Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma. Npj Precis Oncol. 2022;6:1. https:\/\/doi.org\/10.1038\/s41698-021-00245-5.","journal-title":"Npj Precis Oncol"},{"key":"408_CR207","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77:1745\u201370. https:\/\/doi.org\/10.1007\/s00018-019-03351-7.","journal-title":"Cell Mol Life Sci"},{"key":"408_CR208","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2017.05.014","volume":"67","author":"J Calderaro","year":"2017","unstructured":"Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouz\u00e9 E, Blanc J-F, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67:727\u201338. https:\/\/doi.org\/10.1016\/j.jhep.2017.05.014.","journal-title":"J Hepatol"},{"key":"408_CR209","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1016\/S0021-9258(18)45586-X","volume":"262","author":"HL Hachiya","year":"1987","unstructured":"Hachiya HL, Takayama S, White M, King G. Regulation of insulin receptor internalization in vascular endothelial cells by insulin and phorbol ester. J Biol Chem. 1987;262:6417\u201324. https:\/\/doi.org\/10.1016\/S0021-9258(18)45586-X.","journal-title":"J Biol Chem"},{"key":"408_CR210","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0021-9150(92)90273-J","volume":"92","author":"J Nakao-Hayashi","year":"1992","unstructured":"Nakao-Hayashi J, Ito H, Kanayasu T, Morita I, Murota S. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis. 1992;92:141\u20139.","journal-title":"Atherosclerosis"},{"key":"408_CR211","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00403-008-0921-7","volume":"301","author":"CD Shrader","year":"2009","unstructured":"Shrader CD, Bailey KM, Konat GW, Cilento EV, Reilly FD. Insulin enhances proliferation and viability of human umbilical vein endothelial cells. Arch Dermatol Res. 2009;301:159\u201366. https:\/\/doi.org\/10.1007\/s00403-008-0921-7.","journal-title":"Arch Dermatol Res"},{"key":"408_CR212","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1161\/01.CIR.101.13.1539","volume":"101","author":"G Zeng","year":"2000","unstructured":"Zeng G, Nystrom FH, Ravichandran LV, Cong L-N, Kirby M, Mostowski H, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000;101:1539\u201345. https:\/\/doi.org\/10.1161\/01.CIR.101.13.1539.","journal-title":"Circulation"},{"key":"408_CR213","doi-asserted-by":"publisher","first-page":"2303259","DOI":"10.1002\/advs.202303259","volume":"10","author":"SM Andrabi","year":"2023","unstructured":"Andrabi SM, Sharma NS, Karan A, Shahriar SMS, Cordon B, Ma B, et al. Nitric oxide: physiological functions, delivery, and biomedical applications. Adv Sci. 2023;10:2303259. https:\/\/doi.org\/10.1002\/advs.202303259.","journal-title":"Adv Sci"},{"key":"408_CR214","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1023\/A:1006431309841","volume":"50","author":"M Ziche","year":"2000","unstructured":"Ziche M, Morbidelli L. Nitric oxide and angiogenesis. J Neurooncol. 2000;50:139\u201348. https:\/\/doi.org\/10.1023\/A:1006431309841.","journal-title":"J Neurooncol"},{"key":"408_CR215","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(00)00256-4","volume":"2","author":"PK Lala","year":"2001","unstructured":"Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2001;2:149\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(00)00256-4.","journal-title":"Lancet Oncol"},{"key":"408_CR216","doi-asserted-by":"publisher","first-page":"25","DOI":"10.20892\/j.issn.2095-3941.2022.0449","volume":"20","author":"C Yao","year":"2023","unstructured":"Yao C, Wu S, Kong J, Sun Y, Bai Y, Zhu R, et al. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies. Cancer Biol Med. 2023;20:25\u201343. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2022.0449.","journal-title":"Cancer Biol Med"},{"key":"408_CR217","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.canlet.2006.01.008","volume":"242","author":"R Pang","year":"2006","unstructured":"Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 2006;242:151\u201367. https:\/\/doi.org\/10.1016\/j.canlet.2006.01.008.","journal-title":"Cancer Lett"},{"key":"408_CR218","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1007\/s11033-011-1304-2","volume":"39","author":"L Zhang","year":"2012","unstructured":"Zhang L, Wang J-N, Tang J-M, Kong X, Yang J-Y, Zheng F, et al. VEGF is essential for the growth and migration of human hepatocellular carcinoma cells. Mol Biol Rep. 2012;39:5085\u201393. https:\/\/doi.org\/10.1007\/s11033-011-1304-2.","journal-title":"Mol Biol Rep"},{"key":"408_CR219","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.5858\/2000-124-1061-IEOVEG","volume":"124","author":"YN Park","year":"2000","unstructured":"Park YN, Kim Y-B, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med. 2000;124:1061\u20135. https:\/\/doi.org\/10.5858\/2000-124-1061-IEOVEG.","journal-title":"Arch Pathol Lab Med"},{"key":"408_CR220","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.3748\/wjg.v11.i38.5978","volume":"11","author":"J-G Qiao","year":"2005","unstructured":"Qiao J-G, Wu L, Lei D-X, Wang L. Insulin promotes sinusoidal endothelial cell proliferation mediated by upregulation of vascular endothelial growth factor in regenerating rat liver after partial hepatectomy. World J Gastroenterol WJG. 2005;11:5978. https:\/\/doi.org\/10.3748\/wjg.v11.i38.5978.","journal-title":"World J Gastroenterol WJG"},{"key":"408_CR221","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41388-022-02197-x","volume":"41","author":"L Han","year":"2022","unstructured":"Han L, Lin X, Yan Q, Gu C, Li M, Pan L, et al. Pbld inhibits angiogenesis via impeding VEGF\/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells. Oncogene. 2022;41:1851\u201365. https:\/\/doi.org\/10.1038\/s41388-022-02197-x.","journal-title":"Oncogene"},{"key":"408_CR222","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1093\/emboj\/17.17.5085","volume":"17","author":"E Zelzer","year":"1998","unstructured":"Zelzer E. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha \/ARNT. EMBO J. 1998;17:5085\u201394. https:\/\/doi.org\/10.1093\/emboj\/17.17.5085.","journal-title":"EMBO J"},{"key":"408_CR223","doi-asserted-by":"publisher","first-page":"27975","DOI":"10.1074\/jbc.M204152200","volume":"277","author":"C Treins","year":"2002","unstructured":"Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase\/target of rapamycin-dependent signaling pathway. J Biol Chem. 2002;277:27975\u201381. https:\/\/doi.org\/10.1074\/jbc.M204152200.","journal-title":"J Biol Chem"},{"key":"408_CR224","doi-asserted-by":"publisher","first-page":"37721","DOI":"10.18632\/oncotarget.26507","volume":"9","author":"RC Pestana","year":"2018","unstructured":"Pestana RC, Hassan MM, Abdel-Wahab R, Abugabal YI, Girard LM, Li D, et al. Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget. 2018;9:37721. https:\/\/doi.org\/10.18632\/oncotarget.26507.","journal-title":"Oncotarget"},{"key":"408_CR225","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/1534734615600590","volume":"14","author":"C Li","year":"2015","unstructured":"Li C, Yu T, Liu Y, Chen X, Zhang X. Topical application of insulin accelerates vessel maturation of wounds by regulating angiopoietin-1 in diabetic mice. Int J Low Extrem Wounds. 2015;14:353\u201364. https:\/\/doi.org\/10.1177\/1534734615600590.","journal-title":"Int J Low Extrem Wounds"},{"key":"408_CR226","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.06.016","volume":"307","author":"S Chandel","year":"2020","unstructured":"Chandel S, Sathis A, Dhar M, Giri H, Nathan AA, Samawar SKR, et al. Hyperinsulinemia promotes endothelial inflammation via increased expression and release of Angiopoietin-2. Atherosclerosis. 2020;307:1\u201310. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.06.016.","journal-title":"Atherosclerosis"},{"key":"408_CR227","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3390\/cancers16061214","volume":"16","author":"H Ghazanfar","year":"2024","unstructured":"Ghazanfar H, Javed N, Qasim A, Zacharia GS, Ghazanfar A, Jyala A, et al. Metabolic dysfunction-associated steatohepatitis and progression to hepatocellular carcinoma: a literature review. Cancers (Basel). 2024;16:1214. https:\/\/doi.org\/10.3390\/cancers16061214.","journal-title":"Cancers (Basel)"},{"key":"408_CR228","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12029-020-00389-w","volume":"52","author":"S El Shorbagy","year":"2021","unstructured":"El Shorbagy S, abuTaleb F, Labib HA, Ebian H, Harb OA, Mohammed MS, et al. Prognostic significance of VEGF and HIF-1 \u03b1 in hepatocellular carcinoma patients receiving sorafenib versus metformin sorafenib combination. J Gastrointest Cancer. 2021;52:269\u201379. https:\/\/doi.org\/10.1007\/s12029-020-00389-w.","journal-title":"J Gastrointest Cancer"},{"key":"408_CR229","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/lci2.71","volume":"4","author":"S Kang","year":"2023","unstructured":"Kang S, Khalil L, McCook-Veal A, Liu Y, Galvin J, Draper A, et al. Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Liver Cancer Int. 2023;4:77\u201388. https:\/\/doi.org\/10.1002\/lci2.71.","journal-title":"Liver Cancer Int"},{"key":"408_CR230","doi-asserted-by":"publisher","first-page":"9063","DOI":"10.1038\/s41467-024-53127-2","volume":"15","author":"C Dos Santos","year":"2024","unstructured":"Dos Santos C, Cambraia A, Shrestha S, Cutler M, Cottam M, Perkins G, et al. Calorie restriction increases insulin sensitivity to promote beta cell homeostasis and longevity in mice. Nat Commun. 2024;15:9063. https:\/\/doi.org\/10.1038\/s41467-024-53127-2.","journal-title":"Nat Commun"},{"key":"408_CR231","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s13679-024-00597-6","volume":"14","author":"D Simancas-Racines","year":"2025","unstructured":"Simancas-Racines D, Annunziata G, Verde L, Fasc\u00ec-Spurio F, Reytor-Gonz\u00e1lez C, Muscogiuri G, et al. Nutritional strategies for battling obesity-linked liver disease: the role of medical nutritional therapy in metabolic dysfunction-associated steatotic liver disease (MASLD) management. Curr Obes Rep. 2025;14:7. https:\/\/doi.org\/10.1007\/s13679-024-00597-6.","journal-title":"Curr Obes Rep"},{"key":"408_CR232","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jhep.2024.06.017","volume":"81","author":"JM Mucinski","year":"2024","unstructured":"Mucinski JM, Salvador AF, Moore MP, Fordham TM, Anderson JM, Shryack G, et al. Histological improvements following energy restriction and exercise: the role of insulin resistance in resolution of MASH. J Hepatol. 2024;81:781\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.017.","journal-title":"J Hepatol"},{"key":"408_CR233","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s10620-022-07601-w","volume":"68","author":"K DiJoseph","year":"2023","unstructured":"DiJoseph K, Thorp A, Harrington A, Schmitz KH, Chinchilli VM, Stine JG. Physical activity and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Dig Dis Sci. 2023;68:1051\u20139. https:\/\/doi.org\/10.1007\/s10620-022-07601-w.","journal-title":"Dig Dis Sci"},{"key":"408_CR234","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","volume":"20","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH. Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023;20:708\u201322. https:\/\/doi.org\/10.1038\/s41575-023-00800-4.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"408_CR235","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.clnu.2022.08.018","volume":"41","author":"J Zheng","year":"2022","unstructured":"Zheng J, Zhao L, Dong J, Chen H, Li D, Zhang X, et al. The role of dietary factors in nonalcoholic fatty liver disease to hepatocellular carcinoma progression: a systematic review. Clin Nutr. 2022;41:2295\u2013307.","journal-title":"Clin Nutr"},{"key":"408_CR236","doi-asserted-by":"publisher","unstructured":"Long L, Liu X, Petrick J, Liu W, Lee JK, Liao L, et al. Dietary inflammatory and insulinemic potential, risk of hepatocellular carcinoma, and chronic liver disease mortality. JNCI Cancer Spectr. 2023;7. https:\/\/doi.org\/10.1093\/jncics\/pkad023.","DOI":"10.1093\/jncics\/pkad023"},{"key":"408_CR237","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12944-023-01982-1","volume":"22","author":"X Chen","year":"2023","unstructured":"Chen X, Gu J, Huang Y. High dietary intake of unsaturated fatty acids is associated with improved insulin resistance \u2013 a cross-sectional study based on the NHANES database. Lipids Health Dis. 2023;22:216. https:\/\/doi.org\/10.1186\/s12944-023-01982-1.","journal-title":"Lipids Health Dis"},{"key":"408_CR238","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jhep.2022.09.019","volume":"78","author":"P-C Tsai","year":"2023","unstructured":"Tsai P-C, Kuo H-T, Hung C-H, Tseng K-C, Lai H-C, Peng C-Y, et al. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J Hepatol. 2023;78:281\u201392. https:\/\/doi.org\/10.1016\/j.jhep.2022.09.019.","journal-title":"J Hepatol"},{"key":"408_CR239","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/JS9.0000000000001872","volume":"111","author":"L Chen","year":"2025","unstructured":"Chen L, Wu L, Zhang L, Sun B, Wu W, Lei Y, et al. Effect of metformin on hepatocellular carcinoma patients with type II diabetes receiving transarterial chemoembolization: a multicenter retrospective cohort study. Int J Surg. 2025;111:828. https:\/\/doi.org\/10.1097\/JS9.0000000000001872.","journal-title":"Int J Surg"},{"key":"408_CR240","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/MEG.0000000000002754","volume":"36","author":"S Peppas","year":"2024","unstructured":"Peppas S, Doumas S, Suvarnakar A, Chou J, Arafat A, Ahmad AI, et al. Clinical outcomes with metformin use in diabetic patients with compensated cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2024;36:674. https:\/\/doi.org\/10.1097\/MEG.0000000000002754.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"408_CR241","doi-asserted-by":"publisher","first-page":"155516","DOI":"10.1016\/j.metabol.2023.155516","volume":"141","author":"J Park","year":"2023","unstructured":"Park J, Rah S-Y, An HS, Lee JY, Roh GS, Ryter SW, et al. Metformin-induced TTP mediates communication between Kupffer cells and hepatocytes to alleviate hepatic steatosis by regulating lipophagy and necroptosis. Metabolism. 2023;141:155516. https:\/\/doi.org\/10.1016\/j.metabol.2023.155516.","journal-title":"Metabolism"},{"key":"408_CR242","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","volume":"19","author":"M Foretz","year":"2023","unstructured":"Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023;19:460\u201376. https:\/\/doi.org\/10.1038\/s41574-023-00833-4.","journal-title":"Nat Rev Endocrinol"},{"key":"408_CR243","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/hep.25509","volume":"55","author":"C-H Chang","year":"2012","unstructured":"Chang C-H, Lin J-W, Wu L-C, Lai M-S, Chuang L-M, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 2012;55:1462\u201372. https:\/\/doi.org\/10.1002\/hep.25509.","journal-title":"Hepatology"},{"key":"408_CR244","doi-asserted-by":"publisher","unstructured":"Wang Z, Du H, Zhao Y, Ren Y, Ma C, Chen H, et al. Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials. Front Endocrinol. 2023;14. https:\/\/doi.org\/10.3389\/fendo.2023.1111430.","DOI":"10.3389\/fendo.2023.1111430"},{"key":"408_CR245","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/hep.23270","volume":"51","author":"V Ratziu","year":"2010","unstructured":"Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatol Baltim Md. 2010;51:445\u201353. https:\/\/doi.org\/10.1002\/hep.23270.","journal-title":"Hepatol Baltim Md"},{"key":"408_CR246","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/lci2.36","volume":"2","author":"C Hollande","year":"2021","unstructured":"Hollande C, Boussier J, Mottez E, Bondet V, Buivan TP, Charbit B, et al. Safety of sitagliptin in treatment of hepatocellular carcinoma in chronic liver disease patients. Liver Cancer Int. 2021;2:73\u201381. https:\/\/doi.org\/10.1002\/lci2.36.","journal-title":"Liver Cancer Int"},{"key":"408_CR247","doi-asserted-by":"publisher","unstructured":"Wang X, Zhao B, Sun H, You H, Qu S. Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease. Front Endocrinol. 2022;13. https:\/\/doi.org\/10.3389\/fendo.2022.866189.","DOI":"10.3389\/fendo.2022.866189"},{"key":"408_CR248","doi-asserted-by":"publisher","unstructured":"Doustmohammadian A, Nezhadisalami A, Safarnezhad Tameshke F, Motamed N, Maadi M, Farahmand M, et al. A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes. Front Med. 2022;9. https:\/\/doi.org\/10.3389\/fmed.2022.937554.","DOI":"10.3389\/fmed.2022.937554"},{"key":"408_CR249","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.freeradbiomed.2025.06.048","volume":"238","author":"Y-T Chang","year":"2025","unstructured":"Chang Y-T, Chang C-C, Chang M-J, Shieh J-J, Wu M-J. Targeting the NRF2 pathway with linagliptin to inhibit human hepatocellular carcinoma growth. Free Radic Biol Med. 2025;238:303\u201315. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2025.06.048.","journal-title":"Free Radic Biol Med"},{"key":"408_CR250","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/dom.14263","volume":"23","author":"Y Komorizono","year":"2021","unstructured":"Komorizono Y, Hosoyamada K, Imamura N, Kajiya S, Hashiguchi Y, Ueyama N, et al. Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: an analysis of the J-LINK study. Diabetes Obes Metab. 2021;23:832\u20137. https:\/\/doi.org\/10.1111\/dom.14263.","journal-title":"Diabetes Obes Metab"},{"key":"408_CR251","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1177\/09603271211008496","volume":"40","author":"AM Kabel","year":"2021","unstructured":"Kabel AM, Arab HH, Abd Elmaaboud MA. Attenuation of diethyl nitrosamine-induced hepatocellular carcinoma by taxifolin and\/or alogliptin: the interplay between toll-like receptor 4, transforming growth factor beta-1, and apoptosis. Hum Exp Toxicol. 2021;40:1710\u201320. https:\/\/doi.org\/10.1177\/09603271211008496.","journal-title":"Hum Exp Toxicol"},{"key":"408_CR252","doi-asserted-by":"publisher","first-page":"154833","DOI":"10.1016\/j.prp.2023.154833","volume":"250","author":"OA Mohammed","year":"2023","unstructured":"Mohammed OA. Alogliptin exhibits multifaceted effects in thioacetamide-insulted rats: a novel approach to combating hepatic inflammation and fibrogenesis. Pathol - Res Pract. 2023;250:154833. https:\/\/doi.org\/10.1016\/j.prp.2023.154833.","journal-title":"Pathol - Res Pract"},{"key":"408_CR253","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/ijms21165722","volume":"21","author":"M Kojima","year":"2020","unstructured":"Kojima M, Takahashi H, Kuwashiro T, Tanaka K, Mori H, Ozaki I, et al. Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis. Int J Mol Sci. 2020;21:5722. https:\/\/doi.org\/10.3390\/ijms21165722.","journal-title":"Int J Mol Sci"},{"key":"408_CR254","doi-asserted-by":"publisher","unstructured":"So JE, Jeong J, Hong JP, Kim DY, Lee JS, Kim MN, et al. The Impact of Liraglutide on Patients With Metabolic Dysfunction\u2013Associated Steatotic Liver Disease. J Gastroenterol Hepatol. n.d.;n\/a. https:\/\/doi.org\/10.1111\/jgh.70134.","DOI":"10.1111\/jgh.70134"},{"key":"408_CR255","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12072-024-10752-9","volume":"19","author":"C-C Kuo","year":"2025","unstructured":"Kuo C-C, Chuang M-H, Li C-H, Huang P-Y, Kuo H-T, Lai C-C. Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study. Hepatol Int. 2025;19:395\u2013404. https:\/\/doi.org\/10.1007\/s12072-024-10752-9.","journal-title":"Hepatol Int"},{"key":"408_CR256","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.1038\/s41467-024-50660-y","volume":"15","author":"B-K Jeong","year":"2024","unstructured":"Jeong B-K, Choi W-I, Choi W, Moon J, Lee WH, Choi C, et al. A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma. Nat Commun. 2024;15:6506. https:\/\/doi.org\/10.1038\/s41467-024-50660-y.","journal-title":"Nat Commun"},{"key":"408_CR257","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"key":"408_CR258","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41419-019-1646-6","volume":"10","author":"M-H Hung","year":"2019","unstructured":"Hung M-H, Chen Y-L, Chen L-J, Chu P-Y, Hsieh F-S, Tsai M-H, et al. Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced \u03b2-catenin activation. Cell Death Dis. 2019;10:420. https:\/\/doi.org\/10.1038\/s41419-019-1646-6.","journal-title":"Cell Death Dis"},{"key":"408_CR259","doi-asserted-by":"publisher","unstructured":"Lu M, Zhao Y, Liu Z, Zhang Y, Liu J. Canagliflozin Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease via Mitochondrial Protection and Enhanced Mitophagy. Hepatol Res Off J Jpn Soc Hepatol. 2025. https:\/\/doi.org\/10.1111\/hepr.70021.","DOI":"10.1111\/hepr.70021"},{"key":"408_CR260","doi-asserted-by":"publisher","first-page":"177320","DOI":"10.1016\/j.ejphar.2025.177320","volume":"992","author":"L Chen","year":"2025","unstructured":"Chen L, Liu Q, Li X, Zhang L, Dong W, Li Q, et al. The diabetes medication Canagliflozin attenuates alcoholic liver disease by reducing hepatic lipid accumulation via SIRT1-AMPK-mTORC1 signaling pathway. Eur J Pharmacol. 2025;992:177320. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177320.","journal-title":"Eur J Pharmacol"},{"key":"408_CR261","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1210\/clinem\/dgad249","volume":"108","author":"AN Borisov","year":"2023","unstructured":"Borisov AN, Kutz A, Christ ER, Heim MH, Ebrahimi F. Canagliflozin and metabolic associated fatty liver disease in patients with diabetes mellitus: new insights from CANVAS. J Clin Endocrinol Metab. 2023;108:2940\u20139. https:\/\/doi.org\/10.1210\/clinem\/dgad249.","journal-title":"J Clin Endocrinol Metab"},{"key":"408_CR262","doi-asserted-by":"publisher","first-page":"112455","DOI":"10.1016\/j.biopha.2021.112455","volume":"145","author":"AM Abdelhamid","year":"2022","unstructured":"Abdelhamid AM, Saber S, Youssef ME, Gaafar AGA, Eissa H, Abd-Eldayem MA, et al. Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: emerging approach for new application. Biomed Pharmacother. 2022;145:112455. https:\/\/doi.org\/10.1016\/j.biopha.2021.112455.","journal-title":"Biomed Pharmacother"},{"key":"408_CR263","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","volume":"12","author":"H Chehrehgosha","year":"2021","unstructured":"Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, Malek M, Reza Babaei M, Zamani F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther. 2021;12:843\u201361. https:\/\/doi.org\/10.1007\/s13300-021-01011-3.","journal-title":"Diabetes Ther"},{"key":"408_CR264","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12916-025-04017-x","volume":"23","author":"M Lee","year":"2025","unstructured":"Lee M, Hong S, Cho Y, Rhee H, Yu MH, Bae J, et al. Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial. BMC Med. 2025;23:266. https:\/\/doi.org\/10.1186\/s12916-025-04017-x.","journal-title":"BMC Med"},{"key":"408_CR265","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/gutjnl-2011-301708","volume":"62","author":"H-P Chen","year":"2013","unstructured":"Chen H-P, Shieh J-J, Chang C-C, Chen T-T, Lin J-T, Wu M-S, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013;62:606\u201315. https:\/\/doi.org\/10.1136\/gutjnl-2011-301708.","journal-title":"Gut"},{"key":"408_CR266","doi-asserted-by":"publisher","first-page":"2007149","DOI":"10.1002\/adfm.202007149","volume":"31","author":"C Hu","year":"2021","unstructured":"Hu C, He X, Chen Y, Yang X, Qin L, Lei T, et al. Metformin mediated PD-L1 downregulation in combination with photodynamic-immunotherapy for treatment of breast cancer. Adv Funct Mater. 2021;31:2007149. https:\/\/doi.org\/10.1002\/adfm.202007149.","journal-title":"Adv Funct Mater"},{"key":"408_CR267","doi-asserted-by":"publisher","unstructured":"Finisguerra V, Dvorakova T, Formenti M, Van Meerbeeck P, Mignion L, Gallez B, et al. Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression. J Immunother Cancer. 2023;11. https:\/\/doi.org\/10.1136\/jitc-2022-005719.","DOI":"10.1136\/jitc-2022-005719"},{"key":"408_CR268","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tem.2012.03.001","volume":"23","author":"B Cariou","year":"2012","unstructured":"Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPAR\u03b3 agonists: time for a reassessment. Trends Endocrinol Metab. 2012;23:205\u201315. https:\/\/doi.org\/10.1016\/j.tem.2012.03.001.","journal-title":"Trends Endocrinol Metab"},{"key":"408_CR269","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","volume":"20","author":"RE Soccio","year":"2014","unstructured":"Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014;20:573\u201391. https:\/\/doi.org\/10.1016\/j.cmet.2014.08.005.","journal-title":"Cell Metab"},{"key":"408_CR270","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/1061186X.2020.1844216","volume":"29","author":"Y-F Dang","year":"2021","unstructured":"Dang Y-F, Yang S-H, Jiang X-N, Gong F-L, Yang X-X, Cheng Y-N, et al. Combination treatment strategies with a focus on rosiglitazone and adriamycin for insulin resistant liver cancer. J Drug Target. 2021;29:336\u201348. https:\/\/doi.org\/10.1080\/1061186X.2020.1844216.","journal-title":"J Drug Target"},{"key":"408_CR271","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","volume":"16","author":"CF Deacon","year":"2020","unstructured":"Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16:642\u201353. https:\/\/doi.org\/10.1038\/s41574-020-0399-8.","journal-title":"Nat Rev Endocrinol"},{"key":"408_CR272","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jcmgh.2018.08.008","volume":"7","author":"S Nishina","year":"2019","unstructured":"Nishina S, Yamauchi A, Kawaguchi T, Kaku K, Goto M, Sasaki K, et al. Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice. Cell Mol Gastroenterol Hepatol. 2019;7:115\u201334. https:\/\/doi.org\/10.1016\/j.jcmgh.2018.08.008.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"408_CR273","doi-asserted-by":"publisher","first-page":"711723","DOI":"10.3389\/fpubh.2021.711723","volume":"9","author":"W-H Hsu","year":"2021","unstructured":"Hsu W-H, Sue S-P, Liang H-L, Tseng C-W, Lin H-C, Wen W-L, et al. Dipeptidyl peptidase 4 inhibitors decrease the risk of hepatocellular carcinoma in patients with chronic hepatitis C infection and type 2 diabetes mellitus: a nationwide study in Taiwan. Front Public Health. 2021;9:711723. https:\/\/doi.org\/10.3389\/fpubh.2021.711723.","journal-title":"Front Public Health"},{"key":"408_CR274","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41598-020-57935-6","volume":"10","author":"M Kawakubo","year":"2020","unstructured":"Kawakubo M, Tanaka M, Ochi K, Watanabe A, Saka-Tanaka M, Kanamori Y, et al. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis\u2013associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects. Sci Rep. 2020;10:983. https:\/\/doi.org\/10.1038\/s41598-020-57935-6.","journal-title":"Sci Rep"},{"key":"408_CR275","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12072-020-10122-1","volume":"15","author":"F-S Yen","year":"2021","unstructured":"Yen F-S, Wei JC-C, Yip H-T, Hwu C-M, Hou M-C, Hsu C-C. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan. Hepatol Int. 2021;15:179\u201390. https:\/\/doi.org\/10.1007\/s12072-020-10122-1.","journal-title":"Hepatol Int"},{"key":"408_CR276","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","volume":"178","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes. Ann Intern Med. 2025;178:199\u2013217. https:\/\/doi.org\/10.7326\/ANNALS-24-01590.","journal-title":"Ann Intern Med"},{"key":"408_CR277","doi-asserted-by":"publisher","first-page":"e2314493","DOI":"10.1001\/jamanetworkopen.2023.14493","volume":"6","author":"AR Saxena","year":"2023","unstructured":"Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, et al. Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial. JAMA Netw Open. 2023;6:e2314493. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.14493.","journal-title":"JAMA Netw Open"},{"key":"408_CR278","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","volume":"184","author":"F Kanwal","year":"2024","unstructured":"Kanwal F, Kramer JR, Li L, Yang Y-X, Cao Y, Yu X, et al. GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease. JAMA Intern Med. 2024;184:1314\u201323. https:\/\/doi.org\/10.1001\/jamainternmed.2024.4661.","journal-title":"JAMA Intern Med"},{"key":"408_CR279","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.2337\/dc13-0387","volume":"36","author":"RA DeFronzo","year":"2013","unstructured":"DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36:3169\u201376. https:\/\/doi.org\/10.2337\/dc13-0387.","journal-title":"Diabetes Care"},{"key":"408_CR280","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.diabres.2019.01.029","volume":"149","author":"Y Koike","year":"2019","unstructured":"Koike Y, Shirabe S-I, Maeda H, Yoshimoto A, Arai K, Kumakura A, et al. Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019;149:140\u20136. https:\/\/doi.org\/10.1016\/j.diabres.2019.01.029.","journal-title":"Diabetes Res Clin Pract"},{"key":"408_CR281","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","volume":"33","author":"T Sen","year":"2021","unstructured":"Sen T, Heerspink HJL. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metab. 2021;33:732\u20139. https:\/\/doi.org\/10.1016\/j.cmet.2021.02.016.","journal-title":"Cell Metab"},{"key":"408_CR282","doi-asserted-by":"publisher","first-page":"115119","DOI":"10.1016\/j.ejmech.2023.115119","volume":"249","author":"A Mushtaq","year":"2023","unstructured":"Mushtaq A, Azam U, Mehreen S, Naseer MM. Synthetic \u03b1-glucosidase inhibitors as promising anti-diabetic agents: recent developments and future challenges. Eur J Med Chem. 2023;249:115119. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115119.","journal-title":"Eur J Med Chem"},{"key":"408_CR283","doi-asserted-by":"publisher","unstructured":"Yen F-S, Hou M-C, Wei JC-C, Shih Y-H, Hsu CY, Hsu C-C, et al. Liver-related long-term outcomes of alpha-glucosidase inhibitors in patients with diabetes and liver cirrhosis. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.1049094.","DOI":"10.3389\/fphar.2022.1049094"},{"key":"408_CR284","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-021-00690-0","volume":"21","author":"F-S Yen","year":"2021","unstructured":"Yen F-S, Wei JC-C, Lin M-C, Hsu C-C, Hwu C-M. Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes. BMC Endocr Disord. 2021;21:1\u201310. https:\/\/doi.org\/10.1186\/s12902-021-00690-0.","journal-title":"BMC Endocr Disord"},{"key":"408_CR285","doi-asserted-by":"publisher","first-page":"111781","DOI":"10.1016\/j.diabres.2024.111781","volume":"214","author":"F Baccetti","year":"2024","unstructured":"Baccetti F, Crisafulli C, Andreozzi F, Mannino GC, Nicolucci A, Michelli A, et al. Profiles of sulfonylurea use in diabetes mellitus type 2: an analysis of clinical practice over the last 10 years. Diabetes Res Clin Pract. 2024;214:111781. https:\/\/doi.org\/10.1016\/j.diabres.2024.111781.","journal-title":"Diabetes Res Clin Pract"},{"key":"408_CR286","doi-asserted-by":"publisher","first-page":"eabq4126","DOI":"10.1126\/scitranslmed.abq4126","volume":"15","author":"H Watanabe","year":"2023","unstructured":"Watanabe H, Du W, Son J, Sui L, Asahara S-I, Kurland IJ, et al. Cyb5r3-based mechanism and reversal of secondary failure to sulfonylurea in diabetes. Sci Transl Med. 2023;15:eabq4126. https:\/\/doi.org\/10.1126\/scitranslmed.abq4126.","journal-title":"Sci Transl Med"},{"key":"408_CR287","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K, Kita Y, Takata N, Tsujiguchi H, et al. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care. 2022;45:2064\u201375. https:\/\/doi.org\/10.2337\/dc21-2049.","journal-title":"Diabetes Care"},{"key":"408_CR288","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/cncr.24982","volume":"116","author":"MM Hassan","year":"2010","unstructured":"Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010;116:1938\u201346. https:\/\/doi.org\/10.1002\/cncr.24982.","journal-title":"Cancer"},{"key":"408_CR289","doi-asserted-by":"publisher","first-page":"8532","DOI":"10.1038\/s41598-019-44447-1","volume":"9","author":"J-Y Lee","year":"2019","unstructured":"Lee J-Y, Jang S-Y, Nam CM, Kang ES. Incident hepatocellular carcinoma risk in patients treated with a sulfonylurea: a nationwide, nested, case-control study. Sci Rep. 2019;9:8532. https:\/\/doi.org\/10.1038\/s41598-019-44447-1.","journal-title":"Sci Rep"},{"key":"408_CR290","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE. Wong VW-S, Rinella M. Non-alcoholic fatty liver disease The Lancet. 2021;397:2212\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(20)32511-3.","journal-title":"Non-alcoholic fatty liver disease The Lancet"},{"key":"408_CR291","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/cld.569","volume":"8","author":"M Allaire","year":"2016","unstructured":"Allaire M, Nault JC. Type 2 diabetes\u2013associated hepatocellular carcinoma: a molecular profile. Clin Liver Dis. 2016;8:53. https:\/\/doi.org\/10.1002\/cld.569.","journal-title":"Clin Liver Dis"},{"key":"408_CR292","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/COC.0000000000000388","volume":"41","author":"A Gupta","year":"2018","unstructured":"Gupta A, Das A, Majumder K, Arora N, Mayo HG, Singh PP, et al. Obesity is independently associated with increased risk of hepatocellular cancer\u2013related mortality: a systematic review and meta-analysis. Am J Clin Oncol. 2018;41:874\u201381. https:\/\/doi.org\/10.1097\/COC.0000000000000388.","journal-title":"Am J Clin Oncol"},{"key":"408_CR293","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3350\/cmh.2024.0038","volume":"30","author":"P-C Tsai","year":"2024","unstructured":"Tsai P-C, Huang C-F, Yeh M-L, Hsieh M-H, Kuo H-T, Hung C-H, et al. Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy. Clin Mol Hepatol. 2024;30:468\u201386. https:\/\/doi.org\/10.3350\/cmh.2024.0038.","journal-title":"Clin Mol Hepatol"},{"key":"408_CR294","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/hep.30319","volume":"70","author":"JM Banales","year":"2019","unstructured":"Banales JM, I\u00f1arrairaegui M, Arbelaiz A, Milkiewicz P, Muntan\u00e9 J, Mu\u00f1oz-Bellvis L, et al. Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis. Hepatology. 2019;70:547\u201362. https:\/\/doi.org\/10.1002\/hep.30319.","journal-title":"Hepatology"},{"key":"408_CR295","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/hep.29561","volume":"67","author":"P Luo","year":"2018","unstructured":"Luo P, Yin P, Hua R, Tan Y, Li Z, Qiu G, et al. A large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology. 2018;67:662\u201375. https:\/\/doi.org\/10.1002\/hep.29561.","journal-title":"Hepatology"},{"key":"408_CR296","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.2337\/db13-0639","volume":"62","author":"RA Haeusler","year":"2013","unstructured":"Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12\u03b1-hydroxylated bile acids. Diabetes. 2013;62:4184\u201391. https:\/\/doi.org\/10.2337\/db13-0639.","journal-title":"Diabetes"},{"key":"408_CR297","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41574-019-0266-7","volume":"15","author":"TR Ahmad","year":"2019","unstructured":"Ahmad TR, Haeusler RA. Bile acids in glucose metabolism and insulin signalling\u2014mechanisms and research needs. Nat Rev Endocrinol. 2019;15:701\u201312. https:\/\/doi.org\/10.1038\/s41574-019-0266-7.","journal-title":"Nat Rev Endocrinol"},{"key":"408_CR298","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jhep.2010.04.035","volume":"53","author":"G Nkontchou","year":"2010","unstructured":"Nkontchou G, Bastard J-P, Ziol M, Aout M, Cosson E, Ganne-Carrie N, et al. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol. 2010;53:827\u201333. https:\/\/doi.org\/10.1016\/j.jhep.2010.04.035.","journal-title":"J Hepatol"},{"key":"408_CR299","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.3748\/wjg.v16.i18.2265","volume":"16","author":"C-H Hung","year":"2010","unstructured":"Hung C-H, Wang J-H, Hu T-H, Chen C-H, Chang K-C, Yen Y-H, et al. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol WJG. 2010;16:2265. https:\/\/doi.org\/10.3748\/wjg.v16.i18.2265.","journal-title":"World J Gastroenterol WJG"},{"key":"408_CR300","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3390\/ijms20030605","volume":"20","author":"K Imai","year":"2019","unstructured":"Imai K, Takai K, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Homeostatic model assessment of insulin resistance for predicting the recurrence of hepatocellular carcinoma after curative treatment. Int J Mol Sci. 2019;20:605. https:\/\/doi.org\/10.3390\/ijms20030605.","journal-title":"Int J Mol Sci"},{"key":"408_CR301","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.3390\/nu14234969","volume":"14","author":"J Wang","year":"2022","unstructured":"Wang J, Yan S, Cui Y, Chen F, Piao M, Cui W. The diagnostic and prognostic value of the triglyceride-glucose index in metabolic dysfunction-associated fatty liver disease (MAFLD): a systematic review and meta-analysis. Nutrients. 2022;14:4969. https:\/\/doi.org\/10.3390\/nu14234969.","journal-title":"Nutrients"},{"key":"408_CR302","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/hep.27016","volume":"60","author":"K Aleksandrova","year":"2014","unstructured":"Aleksandrova K, Boeing H, N\u00f6thlings U, Jenab M, Fedirko V, Kaaks R, et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology. 2014;60:858\u201371. https:\/\/doi.org\/10.1002\/hep.27016.","journal-title":"Hepatology"},{"key":"408_CR303","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/gut.51.1.100","volume":"51","author":"K Saito","year":"2002","unstructured":"Saito K, Inoue S, Saito T, Kiso S, Ito N, Tamura S, et al. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut. 2002;51:100\u20134. https:\/\/doi.org\/10.1136\/gut.51.1.100.","journal-title":"Gut"},{"key":"408_CR304","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/1724600818776838","volume":"33","author":"BI Carr","year":"2018","unstructured":"Carr BI, Giannelli G, Guerra V, Giannini EG, Farinati F, Rapaccini GL, et al. Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. Int J Biol Markers. 2018;33:423\u201331. https:\/\/doi.org\/10.1177\/1724600818776838.","journal-title":"Int J Biol Markers"},{"key":"408_CR305","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40170-024-00332-8","volume":"12","author":"G-T Ruan","year":"2024","unstructured":"Ruan G-T, Deng L, Xie H-L, Shi J-Y, Liu X-Y, Zheng X, et al. Systemic inflammation and insulin resistance-related indicator predicts poor outcome in patients with cancer cachexia. Cancer Metab. 2024;12:3. https:\/\/doi.org\/10.1186\/s40170-024-00332-8.","journal-title":"Cancer Metab"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00408-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00408-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00408-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:03:15Z","timestamp":1770768195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00408-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":305,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["408"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00408-5","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}